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1.1 Actin and actin dynamics 
Actin is one of the most abundant proteins in any eukaryotic cell as an essential component 
of the cytoskeleton and plays a central role in a number of motile activities such as cell 
migration, cell division and intracellular transport. It comprises a highly conserved family of 
proteins that fall into three broad classes: α-, β-, and γ-isoforms. It is mainly located in the 
cytoplasm, but it is also found in the nucleus. Actin exists in two principal forms, globular, 
monomeric actin (G-actin), and filamentous polymeric actin (F-actin). The globular form is 
a 43 kDa monomer, while the filamentous form is a long-chained polar polymer. G-actin 
monomers have tight binding sites that enable head-to-tail interactions with two other actin 
monomers, so that they polymerize into thin, flexible F-actin, and F-actin also can 
depolymerize into single G-actin monomers reversibly. So, actin filaments are in a 
continuous state of assembly/disassembly (Fig. 1.1). This steady state is dependent on 
solvent conditions, particularly on the presence of certain actin binding proteins (ABPs) 
and/or actin ligands such as jasplakinolide[1] or latrunculin B[2]. 
 
 
 
Figure 1.1 Actin dynamics-polymerization, depolymerization and branch formation  
The actin polymerization is divided into two steps. 1) Nucleation: G-actin monomers form an unstable 
dimer, and then become stabilized by addition of another G-actin monomer to form a tight trimer. 2) 
Elongation: Actin-trimers then polymerize to form filaments (F-actin) by further G-actin monomer 
addition. Actin binding protein Arp2/3 complex can nucleate filaments from the side of existing 
filaments to allow the filaments branch formation. In the meantime, F-actin can also depolymerize 
into G-actin by losing G-actin monomers from the side of filament. 
 
G-actin F-actin 
depolymerization branch formation 
     Actin monomer 
     ABPs / Actin ligands 
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Actin is a protein with the greatest variety of binding partners (such as ABPs, actin binding 
compounds). Due to its common expression and its many biological functions, actin has not 
been pushed as a clinically relevant drug target. 
1.2 Actin binding proteins 
1.2.1 Actin dynamics is regulated by actin binding proteins 
Actin binds a vast number of proteins called actin binding proteins (ABPs). Actin participates 
in more protein-protein interactions than any other known protein, including the interaction 
of actin with itself and with ABPs[3]. In cells, the assembly and disassembly of actin 
filaments, and also their functions are modulated by various of ABPs [4-6] (Fig. 1.2). The 
activities of these proteins are in turn under the control of specific signaling pathways. Actin 
polymerizes from both ends of the filament, but the rate of polymerization at either end is 
different. The fast-growing end is called the barbed end (or plus-end) and the slow-growing 
end is called pointed end (or minus-end). Actin filaments elongate when ATP-actin 
monomers are combined at the barbed end. As the filament elongating, ATP bound in the 
central cleft of actin is hydrolyzed and phosphate is released. As a result, the ADP-actin 
filament is disassembled by losing monomers from the pointed end. The released ADP-
actin monomers then undergo nucleotide exchange to generate ATP-actin monomers that 
can be used for a new round of polymerization. This typical phenomenon of steady filament 
dissociation/association is called actin treadmilling. For actin alone, the equilibrium is a 
dynamic exchange of monomers between the G-actin and the F-actin pool. This dynamics 
is modulated by various ABPs. These proteins include actin depolymerization proteins (like 
e.g. ADF/cofilin), capping/sequestering proteins (like e.g. thymosin β4, Arp2/3 complex), 
severing proteins (like e.g. gelsolin), actin bundling protein (α-actinin), ABPs that facilitate 
nucleotide exchanging (like e.g. profilin), and ABPs that promote branching (like e.g. Arp2/3 
complex)[6]. 
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Figure 1.2 Actin binding proteins regulate actin dynamics 
The monomer-binding protein ADP/cofilin is involved in binding ADP-actin when it is released from 
pointed end. And profilin facilitates the nucleotide exchange of ADP-actin for ATP-actin and delivers 
the new ATP-actin monomers to barbed ends to facilitate new rounds of polymerization. As a 
monomer-sequestering protein, thymosin β4 can clamp ATP-actin to effectively block both barbed 
and pointed ends, preventing ATP-actin combined into the filaments. So that a large amount of ATP-
monomer actins can be stored. When triggered by a certain signal, a rapid release of thymosin β4 
binding will happen, and leads to a rapid filament extension. ADF/cofilin binds to ADP-F-actin and 
promotes dissociation of ADP-actin from the pointed end of filament, driving actin depolymerization. 
Arp2/3 complex can nucleate filament formation, elongate filaments, and establish branch points in 
actin networks. It also caps the pointed end, reduces the loss of monomers from pointed end and 
thereby leads to rapid filament extension. By contrast, the barbed end cappers such as gelsolin, it 
caps filament barbed end, blocks the addition of new ATP-monomers, controlling the overall length 
of the filament. As an actin bundling protein, α-actinin can form an association of actin filaments[6]. 
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1.2.2 Actin competes with ABPs and actin itself in a limited G-actin pool 
The actin cytoskeleton controls cells interaction with each other and their environment in a 
precise way. This is depending on the rearrangement of actin dynamics which is regulated 
by numerous different actin regulators, such as ABPs. A number of recent findings suggest 
that different actin assembly factors compete with one another for a finite G-actin pool. This 
competition limits actin and actin regulators activities and therefore a specific actin network 
and structures were formed as cell needs. Increasing or decreasing cellular G-actin 
influences the generation of F-actin network. For example, the actin monomer binding 
protein profilin is responsible for producing ATP-G-actin for assembly. Profilin also 
enhances formin-mediated and Ena/VASP-mediated actin filament elongation, leading 
linear filaments assembly[7, 8], which consequently inhibit Arp2/3 complex-mediated actin 
nucleation and branch formation. Thymosin β4 clamps ATP-G-actin and control the amount 
of available ATP-G-actin for assembly. It was found that the formin and Arp2/3 complex 
compete with each other for G-actin and disruption of one frees more actin monomers for 
the other[9]. The competition between actin monomers, F-actin filaments and ABPs for 
binding to the available G-actin pool ensures cytoskeletal homeostasis and coordination 
between the different actin regulators to support dynamic cell behavior. 
1.3 Actin cytoskeleton and disease  
1.3.1 The actin cytoskeleton is involved in fundamental functions in cell 
The actin cytoskeleton (actin and ABPs) plays a key role in intracellular transport, cell 
motility, control of cell shape and polarity, and distribution of macromolecules within cells[10] 
(Fig. 1.3). Reorganization of the actin cytoskeleton and expression of different actin 
isoforms are closely associated with cell differentiation processes[11]. This system is also 
involved in cell division[10]. The actin skeleton was shown to play an important role during 
programmed cell death, especially in apoptosis[12-14]. It has been shown that actin is also 
present in nuclei, where it plays a key role in nuclear matrix association, chromatin 
remodeling, RNA polymerase I, II, and III transcription, and mRNA processing[15].  
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Figure 1.3 Biological functions of actin cytoskeleton in cells 
Cell shape picture is retrieved from http://www.scienceline.ucsb.edu/images/cell-shapes. 
1.3.2 The actin cytoskeleton plays important role in the development of different 
diseases 
The actin cytoskeleton, besides the above-mentioned fundamental functions in cell vital 
activity, also plays a key role in the development of different diseases. The role of the 
cytoskeleton and ABPs in disease is an emerging story. The actin microfilament system is 
involved in oncological processes (cell transformation, invasion[16], and metastasis[17]) 
and tissue fibrosis[18]. In particular, the metastatic disease, or the cancer cells movement, 
is a complex process requiring dramatic remodeling of the cell cytoskeleton[17]. Actin 
dynamics defects are a common feature contributing to neurodegeneration[19, 20]. The 
actin cytoskeleton is essential for invasion and infection by various viruses, bacteria, and 
other parasites[21]. All these processes largely depend on the polymerization and 
depolymerization of actin filaments, and the organization of actin into functional networks is 
of course regulated by ABPs. Factors regulating actin assembly become potential targets 
for preventing dissemination and invasion of tumor cells. Actin-dependent cellular 
processes, including tumor invasion, can be pharmacologically modulated by small-
molecule inhibitors of actin assembly[22]. The inseparable element of the cancer 
progression, Epithelial-to-mesenchymal transition (EMT) and its reverse process MET 
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involve the acquisition of features such as invasiveness and migration potential. And the 
cell movement is due to changes in actin cytoskeleton reorganizations including 
polymerization and depolymerization of actin filaments[23]. The dynamics of this process 
can be regulated by actin-binding proteins such as cofilin-1 (CFL1) or special AT-rich 
sequence-binding protein 1 (SATB1)[24]. Profilin1 is required for normal mouse brain 
development, which relies on profilin1 regulation of actin[25].Thus, a better understanding 
of the molecular mechanisms of ABPs controlling actin cytoskeleton provides cues for the 
treatment of these diseases. The feasibility of modifying the behavior of ABPs as a 
therapeutic approach for disease is a considerable need. 
1.4 Actin binding natural compounds 
1.4.1 Actin binding natural compounds: promising actin targeting compounds in a 
therapeutic setting 
Though actin binding natural compounds are known for more than 45 years[26], none of 
them has made it into clinics yet for reasons of lacking functional selectivity. The large 
number of actin binding compounds we know today is mainly of natural origin (fungi, 
bacteria, marine organisms) and can be roughly divided into two groups: 1) actin filament 
stabilizers (phalloidin 1975[27], jasplakinolide 1994[28]), and 2) actin filament assembly 
inhibitors or destabilizers (kabiramide C 1993[29], latrunculin 1983[30]). The discovery of 
actin binding compounds has immensely fueled our knowledge about the biology of actin, 
and these natural compounds mentioned above have already become standard tools in cell 
biology.  
Although, during the past years, we have learned that the complexity of actin biology goes 
far beyond the regulation of overall polymerization and depolymerization[31]: actin does not 
merely form polymers with other actin molecules and subsequently depolymerize again. 
Rather, ABPs continuously compete with each other for binding sites on actin (e.g. thymosin 
β4 with profilin[32], or MRTF with G-actin[33]) and with actin itself[31]. This complex network 
allows for subtle control of the “actin-interactome” and related cell functions. Small actin-
binding molecular compounds have been found to, in turn, compete with specific actin-
binding proteins. For example, kabiramide C has been shown to compete with actin capping 
proteins like gelsolin in a kind of “molecular mimicry”[34]. This aspect of the interaction 
between small molecular inhibitors and actin has been largely neglected during the 
characterization discovery. The effect of actin-binding compounds on the cellular level has 
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yet to be discovered. And the use of actin targeting natural compounds in a therapeutic 
setting has to be considered in spite of their availability. It would open a new field of 
biological tools or even therapeutic options by developing novel and much more specific 
actin targeting compounds. 
1.4.2 Miuraenamide A - a new actin stabilizer 
Myxobacteria produce a variety of natural compounds that interfere with the dynamics of 
cytoskeleton structures of eukaryotic cells, such as chondramides[35], disorazoles[36], and 
rhizopodins[37]. 
A novel myxobacterial compound miuraenamide A, is presumed to be an actin filament 
stabilizing agent[38]. Miuraenamide A is a cyclodepsipepide antibiotic that was isolated from 
Paraliomixa miuraensis, a slightly halophilic myxobacterium discovered in Japan in 
2006[39]. The absolute stereostructure of miuraenamide A was soon determined in 
2008[40]. Miuraenamide A shows antimicrobial activity, inhibits NADH oxidase, and 
stabilizes actin filaments[38-40]. Miuraenamide A also shows high cytotoxicity to a range of 
tumor cell lines[41]. The β-methoxyacrylate moiety of miuraenamide  A is known to be 
important for its antimicrobial activity[40], but its influence on actin binding is still unclear. 
Comparable biological effects of Miuraenamide A were observed with other 
cyclodepsipeptides, such as chondramide[42] and jasplakinolide[35], which is not surprising 
on the basis of their closely related structures (Fig. 1.4). Owing to its interesting biological 
activities, the synthesis of miuraenamides was soon obtained by a peptide modification 
approach in 2015[41]. Further investigations on the characterization of miuraenamide A 
binding to actin is promising. 
 
 
Figure 1.4 Structures of cyclodepsipeptides 
(adapted from Karmann L et al. 2015[41]) 
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1.4.3 Chivosazole A - a new actin destabilizer 
Chivosazoles are 31-membered macrolides with one oxazol ring that were originally 
discovered in different strains of the myxobacterium Sorangium cellulosum, the main 
representative of which is chivosazole A[43] (Fig. 1.5). The chivosazoles are glycosides of 
6-deoxyglucose derivatives. Additionally, the simple aglycon of chivosazole A, was isolated 
and named chivosazole F. The chivosazole family shows a potent antiproliferative activity 
against different mammalian cell lines including human cancer cell lines. Chivosazoles 
show antimicrobial activity against yeasts and filamentous fungi[43]. Chivozazoles are 
cytotoxic against mouse fibroblasts (L-929), inducing a clearly morphological changes 
different from those induced by rhizopodin. Chivosazoles destabilize pryrene F-actin, while 
rhizopodin and cytochalasin D do not[44]. This reveals that chivosazoles inhibit actin 
polymerization through specific binding to G-actin, thereby leading to disruption of 
cytoskeletal dynamics. The absolute and relative configuration of chivosazole A has been 
assigned in 2007 [45], prompting the chemical synthesis of this very potent natural product. 
The synthesis of the chivosazoles was shown to be feasible in 2017[46]. As a result, the 
exact binding site and action mode of chivosazole A are likely to be distinct, thus making it 
a novel, selective tool for the investigation of actin cytoskeleton, as well as a promising 
antimicrofilament lead candidate for drug discovery. 
 
 
 
 
 
Figure 1.5 Structure of chivosazole A and F 
(adapted from Diestel R et al. 2009[44]) 
1 Introduction 
 
 
10 
1.5  Aim of the study 
We wanted to perform an in-depth characterization of these two novel myxobacterial 
compounds miuraenamide A (in comparison to the classical actin stabilizer jasplakinolide) 
and chivosazole A (in comparison to a structurally unrelated actin filament inhibitor 
latrunculin B[2]) 
 
 in vivo on cellular function and on transcriptional regulation 
 in vitro on actin dynamics and protein-protein-interactions of actin 
 through co-crystallization and structure determination to reveal their actin 
binding mode 
 
in order to find out new and more specific actin targeting compounds and develop them into 
a new field of biological tools or even therapeutic options instead of just “stabilizers” or 
“destabilizers”. 
2 Materials and Methods 
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2.1 Materials 
2.1.1 Compounds 
Miuraenamide A (MiuA) was kindly provided by Prof. Dr. Uli Kazmaier (Institute for Organic 
Chemistry, Saarland University, Saarbrücken, Germany). Jasplakinolide (Jaspla) was 
purchased from Santa Cruz (Heidelberg, Germany). Chivosazole A (ChivoA), Chivosazole 
F (ChivoF) and Rhizopodin were kindly provided by Prof. Dr. Rolf Müller (Helmholtz Center 
for Infection Research, Saarland University, Saarbrücken, Germany), isolated from 
myxobacterial strains. Latrunculin B was purchased from Biomol GmbH (Hamburg, 
Germany). 
All compounds were dissolved in dimethyl sulfoxide (DMSO) and stored at -20 °C. For cell 
experiments, they were further diluted in endothelial cell growth medium (ECGM) with a 
maximum end concentration of DMSO of 0.1% (v/v). For TIRF and actin-binding 
experiments, they were further diluted in DMSO. 
2.1.2 Chemicals and reagents 
The following table contains a list of all chemicals, reagents and kits used in this study. 
Buffers and solutions are listed separately. 
 
Table 2.1: Chemicals and reagents 
Reagent Producer 
Adenosine 5′-triphosphate (ATP) Sigma-Aldrich, Taufkirchen, Germany 
Actin (rabbit skeletal muscle) Hypermol, Bielefeld, Germany 
Actin-Toolkit G-actin binding Hypermol, Bielefeld, Germany 
Actin-Toolkit F-actin binding Hypermol, Bielefeld, Germany 
α-actinin (turkey gizzard smooth muscle) Hypermol, Bielefeld, Germany 
Arp2/3 complex (porcine brain) Hypermol, Bielefeld, Germany 
ATP-Sucrose cushion Hypermol, Bielefeld, Germany 
Atto488-Actin (rabbit skeletal muscle) Hypermol, Bielefeld, Germany 
Amphotericin B PAN-Biotech, Aidenbach, Germany 
Bovine Serum Albumin (BSA) Sigma-Aldrich, Taufkirchen, Germany 
CaCl2 Sigma-Aldrich, Taufkirchen, Germany 
Catalase Sigma-Aldrich, Taufkirchen, Germany 
2 Materials and Methods 
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Cofilin (non muscle cofilin) Hypermol, Bielefeld, Germany 
Collagen G Biochrom AG, Berlin, Germany 
Coomassie Brilliant Blue R-250 staining solution Bio-Rad, Munich, Germany 
Coomassie Brilliant Blue R-250 destaining solution Bio-Rad, Munich, Germany 
Crystal violet  Carl Roth, Karlsruhe, Germany 
D-glucose Sigma-Aldrich, Taufkirchen, Germany 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, Taufkirchen, Germany 
Dithiothreithol (DTT) 
SERVA Electrophoresis, Heidelberg, 
Germany 
Dulbecco’s Modified Eagle Medium (DMEM) PAA Laboratories, Pasching, Austria 
Endothelial cell growth medium (ECGM) Pelobiotech, Martinsried, Germany 
Ethanol Carl Roth, Karlsruhe, Germany 
Ethylendiaminetetraacetic acid (EDTA) Sigma-Aldrich, Taufkirchen, Germany 
Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-
tetraacetic acid (EGTA) 
Sigma-Aldrich, Taufkirchen, Germany 
F-Actin BufferKit REF 5300-01 Hypermol, Bielefeld, Germany 
Fetal calf serum (FCS) Biochrom AG,Berlin 
FluorSave® reagent mounting medium Merck, Darmstadt, Germany 
Glucose oxidase from Aspergillus Niger Sigma-Aldrich, Taufkirchen, Germany 
GST-VCA (recombinant, human) Hypermol, Bielefeld, Germany 
Hoechst 33342 Sigma-Aldrich, Taufkirchen, Germany 
Imidazole Sigma-Aldrich, Taufkirchen, Germany 
KH2PO4 Carl Roth, Karlsruhe, Germany 
KCl Carl Roth, Karlsruhe, Germany 
Corning®, Matrigel®, REF 356231 Corning, NY, USA 
Methanol Carl Roth, Karlsruhe, Germany 
Methylcellulose Sigma-Aldrich, Taufkirchen, Germany 
MgCl2 AppliChem, Darmstadt, Germany 
MgSO4·7H2O Carl Roth, Karlsruhe, Germany 
Na3C6H5O7 Carl Roth, Karlsruhe, Germany 
NaCl Carl Roth, Karlsruhe, Germany 
Na2HPO4 Merck, Darmstadt, Germany 
Formaldehyde, 16%, methanol free, Ultra Pure Polysciences Inc., Warrington,PA, USA 
Penicillin/Streptomycin PAN Biotech, Aidenbach, Germany 
Prestained protein ladder PageRulerTM  Bio-Rad, Munich, Germany 
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Pyrene Actin 10% (rabbit skeletal muscle) Hypermol, Bielefeld, Germany 
Rhodamin phalloidin Sigma-Aldrich, Taufkirchen, Germany 
Sodium dodecyl sulfate (SDS) Carl Roth, Karlsruhe, Germany 
Streptomycin PAN Biotech, Aidenbach, Germany 
Tris-Base Sigma-Aldrich, Taufkirchen, Germany 
Tris-HCl Sigma-Aldrich, Taufkirchen, Germany 
Triton X-100 Merck, Darmstadt, Germany 
Trypsin PAN Biotech, Aidenbach, Germany 
β-Mercaptoethanol Sigma-Aldrich, Taufkirchen, Germany 
 
Table 2.2: Consumables      
Product Producer 
Cell culture flasks 75cm2 TPP, Trasadingen, Switzerland 
Corning® 96 Well Black Polystyrene 
Microplate REF3686 
Corning Incorparated, NY, USA 
Cover slip (8 × 8 mm) H.Saur Laborbedarf, Reutlingen, Germany 
Cover slip (22 × 22 mm) Th.Geyer GmbH, Renningen, Germany 
Disposable pipettes: 5 ml, 10 ml, 25 ml Greiner Bio, Frickenhausen, Germany 
Falcon tubes: 15 ml, 50 ml VWR, Bruchsal, Germany 
Glass slide (Microscope Slides 76 × 26 mm) Thermo scientific, Braunschweig, Germany 
Microcentrifuge Tubes: 1.5ml Beckman Coulter, Krefeld, Germany 
Microtiter plates: 96 well Greiner Bio, Frickenhausen, Germany 
Microtubes: 1.5 ml, black Carl Roth, Karlsruhe, Germany 
Microtubes: 1.5 ml, brown Sarstedt AG & Co.KG, Nuembrecht, Germay 
Parafilm American National Can, Chicago, USA 
Pipette tips: 10 μl, 100 μl, 1000 μl Sarstedt, Nümbrecht, Germany 
Safe-Lock Tubes: 0.5 ml, 1.5 ml, 2.0 ml Eppendorf, Hamburg, Germany 
μ-Slide 8 Well Ibidi GmbH, Munich, Germany 
μ-Slide Angiogenesis Ibidi GmbH, Munich, Germany 
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μ-Slide Chemotaxis Ibidi GmbH, Munich, Germany 
2.1.3 Technical equipment 
Table 2.3 Technical equipment 
Technical equipment Producer 
Axiovert 25 / m200 Zeiss, Jena, Germany 
ChemiDocTM Touch Imaging System Bio-Rad Laboratories, Munich, Germany 
Digital block heater HX-1 PEQLAB Biotechnologie, Erlangen, Germany 
Heracell CO2 Incubator 150i Thermo Fisher Scientific, MA, USA 
Heraeus Megafuge 1.0 RS centrifuge Kendro Laboratory Products, Hanau, Germany 
Ibidi stage top incubation system Ibidi GmbH, Munich, Germany 
IKA Vibrax VXR Basic shaker IKA-Werke, Staufen Germany 
Infinite® 200 PRO microplate reader Tecan, Männedorf, Switzerland 
LSM 510 Meta confocal microscope Zeiss, Jena, Germany 
Mikro 220 / 220 R microliter centrifuge Hettich, Tuttlingen, Germany 
Mini-PROTEAN® 3 Bio-Rad, Dreieich, Germany 
Nanodrop® ND-1000 Peqlab,Wilmington, USA 
Optima TLX Ultracentrifuge Beckman Coulter, Fullerton, CA, USA 
Power Pac 300 blotting device Bio-Rad, Dreieich, Germany 
SpectraFluor PlusTM  microplate reader Tecan, Männedorf, Switzerland 
Thermo Haake W19 open-bath circulator Thermo Fisher Scientific, MA, USA 
Total internal reflection fluorescence 
microscope (TIRFM) 
Leica Microsystems, Wetzlar, Germany 
Vi-CellTM XR Beckman Coulter, Fullerton, CA, USA 
Nikon inverted microscope Eclipse Ti Nikon corporation, Tokyo, Japan 
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2.2 Methods  
2.2.1 Cell culture 
The human umbilical vein endothelial cells (HUVECs) are primary cells purchased from 
Promocell (Heidelberg, Germany). The company guarantees an ongoing quality control (e.g. 
expression of endothelial markers). Further authentication is not necessary, since these are 
primary cells. The cells were cultured with endothelial cell growth medium (Promocell), 
supplemented with 10% FCS under constant humidity at 37 °C and with 5% CO2. Upon 
confluency, cells were splitted in a ratio 1:3 in a 75 cm2 cell culture flasks. Cells were used 
for functional assays at passage 6. 
 
Table 2.4 Cell culture solutions and reagents 
Endothelial cell growth medium 
(ECGM) 
 Freezing medium 
Endothelial cell growth medium 
(with supplement kit) 
500 ml  DMEM 
FCS 
70% 
20% 
FCS (heated) 50 ml  DMSO 10% 
Amphotericin* 5 ml    
Pen / Strep* 5 ml    
 
 
 
Stopping medium  Starvation medium  
DMEM 500 ml  DMEM 500 ml 
FCS (heated) 50 ml  Amphotericin* 5 ml 
   Pen / Strep* 5 ml 
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PBS (pH 7.4)  PBS+Ca2+/Mg2+ (pH 7.4) 
NaCl 132.2 mM  NaCl 137 mM 
Na2HPO4 10.4 mM  KCl 2.68 mM 
KH2PO4 3.2 mM  Na2HPO4 8.10 mM 
H2O   KH2PO4 1.47 mM 
   MgCl2 0.25 mM 
   H2O  
 
 
Trypsin/EDTA (T/E)  Collagen G 
Trypsin 0.05%  Collagen G 0.001% 
EDTA 0.20%  PBS  
PBS     
* Pen / Strep: Penicillin 10 000 Units/ml, Streptomycin 10 mg/ml 
* Amphotericin: Amphotericin B 250 μg/ml 
2.2.2 Passaging 
For passaging, cell medium was removed, cells were washed twice with PBS and detached 
with 1.5 ml Trypsin/EDTA (37 °C, 3 min). After incubation, tryptic digestion was stopped by 
adding 15 ml stopping medium. Cells were centrifuged (1000 rpm, 5 min, 20 °C), 
resuspended in ECGM. Cell concentration and vitality were determined by using Vi-CellTM 
XR. Then cells were either transferred into a new cell culture flask (75 cm2, pre-coated with 
Collagen G) or seeded for experiments.  
2.2.3 Freezing and thawing 
For long time storage, a 75 cm2 flask of confluent HUVECs were detached by Trypsin/EDTA 
and collected by centrifugation (1000 rpm, 5 min, 20 °C). Cells were then resuspended in 3 
ml ice-cold freezing medium. 1.5 ml aliquots were frozen in cryovials and stored at -80 °C 
for 24 h before being moved to liquid nitrogen (-196 °C) for longtime storage. In order to 
thaw cells, cells in cryovials were immediately dissolved in pre-warmed stopping medium. 
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DMSO was removed by centrifugation, cells were resuspended in 15 ml pre-warmed ECGM 
and transferred into a 75 cm2 flask (pre-coated with Collagen G).  
2.3 Proliferation Assay  
HUVECs (1.5 × 103 cells/well) were seeded in 96-well plates (pre-coated with Collagen G). 
After 24 h incubation, cells in a reference plate were stained with crystal violet and served 
as initial control. The cells in a treatment plate were either left untreated or treated with 
indicated concentrations of compounds respectively for 72 h. After treatment, the medium 
was removed and cells were stained with crystal violet staining solution for 10 min, then 
washed with water and dried overnight. Cell-bound crystal violet was dissolved with sodium 
citrate solution (5 min, shaking) and the absorbance which correlates with cell number was 
measured at 550 nm using a microplate reader (SpectraFluor PlusTM). For statistical 
analysis, cells treated with vehicle control were set to be 100%. 
 
Table 2.5 Crystal violet and sodium citrate buffer. 
Crystal violet staining solution  Sodium citrate solution 
Crystal violet 0.5%  Na3C6H5O7 0.05 M 
Methanol 20%  Ethanol 50% 
H2O  H2O 
2.4 Fluorescence imaging 
HUVECs (25 × 103 cells/well) were seeded in an 8 well ibidi μ-slide (pre-coated with 
Collagen G), pretreated with indicated concentrations of compounds. After 1 h treatment, 
cells were rinsed with PBS + Ca2+/Mg2+ and fixed with 4% (v/v) formaldehyde for 10 min. 
After 5 min washing with PBS, samples were permeabilized for 2 min with 0.2% Triton X-
100 in PBS. After 3 × 5 min washing with PBS, cells were incubated with rhodamine 
phalloidin (1:400) and Hoechst 33342 (1 μg/ml) for 1 h at room temperature, then washed 
again 3 × 5 min with PBS and sealed with one drop of FluorSave reagent mounting medium 
and covered by cover slips (8 × 8 mm). Images were taken using a Zeiss LSM 510 META 
confocal microscope.  
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2.5 Cell migration assay 
2.5.1 Scratch assay 
To examine the migratory ability of HUVEC cells under the influence of various compounds, 
scratch assay was performed first. For the scratch assay, HUVECs were seeded into 96-
well plates (Collagen G pre-coated), incubated overnight. Then confluent HUVECs were 
scratched with a custom-made tool and either left untreated or treated with the indicated 
concentrations of compounds. Cells were allowed to migrate for 16-24 h, then washed with 
100 μl/well PBS (including Mg2+, Ca2+), stained with 100 μl/well Crystal Violet solution for 
10 min, washed with water, and dried. Images were taken using a standard inverted 
microscope. Image analysis was performed with ImageJ. Migration was quantified as the 
percentage of cell covered area compared with the total image area. 
2.5.2 2D and 3D Chemotaxis 
Chemotaxis experiments were conducted according to the manufacturer’s instructions. For 
the 2D-chemotaxis assay, HUVECs (50 × 103/well) were seeded in a μ-Slide Chemotaxis, 
either left untreated or treated with indicated concentrations of compounds and incubated 
to be slightly adherent to the surface of the observation area. After 2 h, ECGM with a 
gradient of FCS between 0 and 10% (v/v) was applied into the slide (Fig. 2.1). For 3D-
chemotaxis assay, HUVECs (50 × 103/well) were seeded in matrigel in the observation area 
of a μ-Slide Chemotaxis, either left untreated or treated as indicated and incubated. After 
0.5 h, ECGM with a gradient FCS between 0 and 10% (v/v) was applied (Fig. 2.2). 
Time lapse image sequences of HUVEC cell migration were taken every 10 min for 21 h 
using a Nikon inverted microscope Eclipse Ti, equipped with ibidi stage top incubation 
system (37 °C, 5% CO2, 80% humidity). Single cell tracking was performed using ImageJ 
software plugin “Manual tracking” (Version 2.0 with ImageJ Plugin). Images were analyzed 
using the Chemotaxis and Migration Tool (ibidi, Martinsried, Germany). Cell mean velocity, 
directness and X-forward migration index (X-FMI) were calculated as parameters.  
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Figure 2.1 2D Chemotaxis experiments without gel 
(adapted from Application note 17: Chemotaxis 2D and 3D, ibidi GmbH, Munich, Germany) 
 
 
Figure 2.2 3D Chemotaxis experiments in matrigel 
(adapted from Application note 17: Chemotaxis 2D and 3D, ibidi GmbH, Munich, Germany) 
2.6 Tube formation assay  
To investigate the effect of our compounds on HUVECs tube formation ability, tube 
formation assay was performed. For tube formation assay, HUVECs (10 × 103 cells/well) 
were seeded in matrigel in a μ-Slide Angiogenesis, either left untreated or treated with 
various compounds as indicated and incubated for tube formation. After 16 h, images of the 
cells were taken using a Nikon standard inverted microscope Eclipse Ti and analyzed by 
Wimasis GmbH (Munich, Germany). As parameters of tube formation, total branching points, 
total loops, total tubes and mean tube length were used. 
 
10%FCS 0%FCS 
Cells 
objective lens 
70 μm 
1 mm 
10%FCS 
 
0%FCS 
 
70 μm 
1 mm 
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2.7 Pyrene assay 
To investigate the effect of our compounds on actin polymerization, pyrene assay was 
performed. This assay is based on the enhanced fluorescence of pyrene conjugated actin 
that occurs during polymerization. The enhanced fluorescence that occurs when pyrene G-
actin (monomer) forms pyrene F-actin can be measured in a fluorimeter to follow 
polymerization over time.  
Pyrene assay was performed using Pyrene Actin (10%) and F-Actin BufferKit according to 
the manufacturer's instructions. Pyrene Actin (10%) was diluted with H2O to a 1 mg/ml (24 
μM) stock solution. Before use, spontaneously formed actin aggregates were removed by 
ultracentrifugation for 1 h at 40,000 rpm and 4 °C. 50 μl samples for the pyrene assay 
consisted of: 30 μl H2O, 10 μl 10 mM MgCl2 or 250 mM KCl, 5 μl F-actin Buffer (100 mM 
Imidazole-Cl pH 7.4, 10 mM ATP) as well as 5 μl DMSO (containing indicated 
concentrations of compounds/proteins) were added into a 96 well black polystyrene 
microplate immediately before the rapid addition of 10 μl pyrene actin to start polymerization. 
Pyrene fluorescence was monitored every 20 s over 1 h in a 96-well fluorescence plate 
reader (Infinite® 200 PRO) at 360 nm excitation and 400 nm emission wavelength.  
2.8 TIRF assays 
2.8.1 Flow cell preparation 
Flow cells containing 15 - 20 μl of fluid were prepared as a sandwich of a cover slip (22 × 
22 mm), 2 parafilm strips forming an approximately 5 mm wide channel, and a glass 
microscope slide (76 × 26 mm). Both, the coverslip and the glass slide were cleaned by 
ethanol and dried. The chamber was heated briefly and cooled to melt the parafilm strips to 
the glass slide surface and the cover slip. For TIRF microscope, chambers were used with 
the cover slip down, facing the objective lens, and slide up (Fig. 2.3). Solutions were loaded 
directly into the chamber via capillary action. 
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Figure 2.3 Scheme of flow cell and the visualization of single actin filaments using TIRF 
microscopy 
Growing actin filaments attach to α-actinin on the coverslip surface. (adapted from Breitsprecher D 
et al. 2009[47]) 
 
2.8.2 Protein and TIRF buffer preparation 
Atto488-Actin and Actin from rabbit skeletal muscle were purchased from Hypermol 
(Bielefeld, Germany). Both Atto488-Actin and Actin were reconstituted with H2O to obtain a 
1 mg/ml stock. Labeled actin was prepared by mixing Atto488-Actin and Actin 1:1 v/v. 
Protein concentration was determined by measuring OD at 290 nm (ε290 = 26,600 M-1cm-1) 
using Nanodrop® ND-1000[48]. 
α-actinin from turkey gizzard smooth muscle was purchased from Hypermol (Bielefeld, 
Germany) and was prepared by adding 1 ml H2O to the tube with α-actinin to obtain a 
working stock of 1 mg/ml. 
 
 
 
 
 
 
 
Cell flow 
Actin filament side binding  
α-actinin 
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Table 2.7 Buffers for TIRF assays 
G-buffer (pH 7.8)  10 × KMEI buffer (pH 7.1) 
Tris-HCl (pH 8.0) 2 mM  KCl 500 mM 
CaCl2 0.2 mM  MgCl2 20 mM 
DTT 0.5 mM  EGTA 20 mM 
ATP 0.2 mM  Imidazole 300 mM 
H2O   H2O  
Added before use:     
MgATP 0.2 mM    
     
 
2 × TIRF buffer (pH 7.4)  F-buffer 
10 × KMEI buffer 20% (v/v)  10 × KMEI buffer 10% (v/v) 
D-glucose 30 mM  G-buffer 90% (v/v) 
Catalase 40 μg/ml    
Glucose oxidase 400 μg/ml   
Methylcellulose 1%(w/v)  10 × Mg exchange buffer  
β-mercaptoethanol 2%(v/v)  MgCl2 400 μM 
G-buffer   EGTA 2 mM 
2.8.3 Nucleation and polymerization assay 
Freshly prepared flow cells were first incubated with 25 μl 1% (w/v) BSA for 10 min, then 
25 μl α-actinin (1 mg/ml) was applied into the flow cell and incubated for 5 min. In the 
meantime, labeled actin (10 μM) was incubated 1:1 v/v with 1/10 volume of 10 × Mg 
exchange buffer and 1:8 v/v with G-buffer for 5 min on ice to convert Ca-ATP-actin to Mg-
ATP-actin. Flow cell was then washed with 30 μl of G-buffer. 2 × Mg-ATP-actin (1 μM) was 
mixed 1:1 v/v with 2 × TIRF buffer containing different compounds as indicated, and the 
polymerization started. 30 μl polymerizing actin were immediately loaded into the flow cell 
chamber and placed on the TIRF microscope to start image acquisition. For nucleation 
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assay, the amount of actin nuclei present in each frame was analyzed using programs 
custom-written in MATLAB (The MathWorks, Natick, MA) R2017a. For polymerization 
assay, fluorescence image sequences of actin polymerization were taken every 1 s for 5 
min. Elongation rates were calculated by Image J software (version 1.49). 
2.8.4 Depolymerization assay 
Labeled F-actin was obtained by incubating labeled actin (10 μM) 1:1 v/v with 1/10 volume 
of 10 × KMEI buffer and 1:8 with G-buffer for 1 h at room temperature. 20 μl 1:4 v/v diluted 
F-actin filaments (with F-buffer) were loaded into a flow cell previously blocked with 1% BSA 
and coated with 1 mg/ml α-actinin. Then 50 μl 2 × TIRF buffer with indicated compounds 
were applied gently into the flow chamber and immediately placed on the TIRF microscope 
to start image acquisition. The real time actin depolymerization process in a single frame 
was captured as image sequence every 15 s for 90 min. The average length of actin 
filaments was quantified as depolymerization parameter by using custom-written programs 
in MATLAB. 
2.8.5 Phalloidin competition assay 
For the phalloidin competition assay, labeled F-actin (prepared as described) was loaded 
into a freshly coated flow cell. TIRF buffer with 16.5 nM rhodamine-phalloidin, as well as 
different concentrations of Miuraenamide A as indicated were applied into the flow chamber 
and immediately placed on the TIRF microscope to start image acquisition. Different frames 
of fluorescent actin filaments were taken. Phalloidin Δintensity and IC 50 of Miuraenamide 
A were calculated by using ImageJ software (version 1.49). 
2.8.6 Branch formation assay 
To observe actin branch formation, labeled actin was incubated with Mg exchange buffer to 
obtain Mg-ATP-actin as described. 2 × Mg-ATP-actin (1 μM) was mixed 1:1 v/v with 2 × 
TIRF buffer containing Arp2/3 complex, GST-VCA and various compounds as indicated, 
then immediately loaded into a coated flow chamber and placed on the TIRF microscope to 
start image acquisition. A single frame of actin fluorescence was recorded every 2 s for 10 
min. 
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2.9 Actin binding assay 
2.9.1 G-actin binding assay 
The G-actin binding assay was performed using ‘Actin-Toolkit G-Actin Binding’ according 
to manufacturer's instructions. In this kit G-actin is coupled to SepharoseTM as G-actin beads. 
Binding of ABPs to G-actin is highly specific, and thus, the ABPs bound to G-actin will be 
co-precipitated under low centrifugal forces. G-actin beads (1/4 volume of 1 tube) were pre-
treated with our compounds as indicated for 30 min at room temperature under agitation, 
then the ABPs (gelsolin, profilin, cofilin or Arp2/3 with GST-VCA) were added respectively, 
incubated for 1 h at room temperature. After incubation, sample was spun (6,000 × g, 4°C, 
4 min) and 40 μl supernatant were mixed with 10 μl 5 × SDS-sample buffer. Then the G-
actin beads were washed, resuspended in 25 μl of 1 × SDS-sample buffer and boiled at 
95°C for 5 min. Both the supernatant and the G-actin beads (15 μl of each) were separately 
loaded onto an SDS-PAGE gel for analysis. After electrophoresis, the gel was stained in 
Coomassie Brilliant Blue R-250 staining solution for 60 min, rinsed in deionized water and 
then fixed in Coomassie Brilliant Blue R-250 destaining solution for 60 min at room 
temperature or overnight at 4°C. The stained gel was imaged using a ChemiDoc Imaging 
System. The amounts of each protein were quantified by using Image Lab 6.0 Software.  
2.9.2 F-actin binding assay 
F-actin binding assay was performed using ‘Actin-Toolkit F-Actin Binding’ according to 
manufacturer's instructions. F-actin is prepared by polymerizing G-actin with PolyMix (1 M 
KCl, 0.02 M MgCl2, 0.01 M ATP, 0.1 M imidazole pH 7.4) for 30 min at room temperature. 
250 μl F-actin sample mix were prepared by incubating F-actin with each of our compounds 
as indicated for 30 min in PolyMix at room temperature, then the respective F-actin binding 
protein (cofiln, gelsolin, or Arp2/3 complex with GST-VCA) was added, incubated for 1 h at 
room temperature (the molar ratio of F-actin and ABP was 1:1). During sample incubation 
the sucrose cushions was prepared by adding 50 μl sucrose solution to the centrifuge tube. 
After incubation, 40 μl of the sample mix were prepared (mixed with 10 μl of 5 × SDS-
sample buffer) for a total SDS-PAGE sample. 200 μl of the rest sample was added into the 
centrifuge tube overlaying the sucrose cushion. Pelleting of F-actin binding proteins was 
achieved by spinning the rest of the sample at 100,000 × g, at 4 °C for 1 h. After 
centrifugation, 40 μl of the supernatant were prepared (mixed with 10 μl of 5 × SDS-sample 
buffer) as a supernatant sample for SDS-PAGE. The pellets were dissolved in 200 μl 1 × 
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SDS-sample buffer, boiled at 95°C for 5 min and then 15 μl of each SDS-sample (total, 
supernatant and pellet) was loaded into an SDS-PAGE gel separately to observe F-actin 
binding after electrophoresis. The gel was then stained by coomassie blue as described in 
G-actin binding assay. After staining the gel was captured by using a ChemiDoc Imaging 
System. The amounts of each protein were quantified by using Image Lab 6.0 Software. 
2.9.3 Crosslink assay 
Cross-linking of thymosin β4 to G-actin was performed by using EDC as a cross-linker. 
Binding of thymosin β4 to G-actin could be detected after crosslinking. The molecular weight 
of cross-link product was approximately 47.5 kDa.  
G-actin (27 μM) was dissolved in crosslink G-buffer (3 mM triethanolamine-HCl, 0.2 mM 
CaCl2, 0.2 mM ATP, NaN3, pH 7.5) and incubated with either ChivoA or LatB as indicated 
at 4 ºC for 30 min. Then thymosin β4 was applied and incubated at 4 ºC for 45 min at a 
weight ratio of 9:1, corresponding to 0.94 molecules of thymosin β4 per actin monomer. 
Aliquots of 10 μl were then mixed with 12.2 μl of 5.4 mM EDC (1-ethyl-3-(3-
dimethylaminopropyl)- carbodiimide) in 0.1 M MES (2-(N-morpholino)-ethanesulfonic acid), 
pH 6.5, and incubated for 2 h at 25 ºC. Equal aliquots were taken up into SDS sample buffer 
and analyzed by SDS-PAGE on a 10% gel to detect cross-link product. After electrophoresis 
gel was then stained by coomassie blue as described in G-actin binding assay. After 
staining the gel was captured by using a ChemiDoc Imaging System. The amounts of each 
protein were quantified by using Image Lab 6.0 Software. Cross-link product was quantified 
as a normalized gray intensity of cross-link product band compared with actin. 
2.9.4 SDS-PAGE 
The SDS-PAGE gels were prepared in a discontinuous manner, with a stacking gel on top 
of the separation gel. The concentrations of acrylamide in the separation gels were adjusted 
to optimize the separation of proteins according to their molecular weights. 
The Mini-PROTEAN 3 electrophoresis module was used. Prior to sample loading, the 
apparatus was assembled according to manufacturer’s protocol and the chamber was filled 
with electrophoresis buffer. Equal amount of samples were loaded on to the stacking gel. 
An equal volume of 1 x SDS-sample buffer containing 2 μl of prestained protein ladder 
PageRulerTM was loaded on each gel to estimate the molecular weights of the separated 
proteins. Electrophoresis was carried out at 100 V for 21 min for protein stacking, then at 
200 V for 35-45 min for protein separation. 
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Table 2.8 Buffers for SDS-PAGE analysis 
5x SDS-sample buffer  1x SDS-sample buffer 
3.125 M Tris-Base, pH6.8 10%  5x SDS sample buffer 20%  
Glycerol 50%  H2O 80% 
SDS 5%    
DTT 2%    
Pyronin Y 0.025%    
in H2O     
 
 
Table 2.9 Acrylamide gels  
Separation gel 10 / 12 / 15 %  Stacking gel 
RotiphoreseTM Gel 30 33/40/50%  RotiphoreseTM Gel 30 17% 
1.5 M Tris-Base (pH 8.8) 25%  1.25 M Tris-Base (pH 6.8) 10% 
SDS 0.1%  SDS 0.1% 
TCE 10%  TEMED 0.2% 
TEMED 0.1%  APS 0.1% 
APS 0.05%  in H2O  
in H2O     
 
 
Table 2.10 Electrophoresis buffer 
Electrophoresis buffer 
Tris-Base 4.9 mM 
Glycine 38 mM 
SDS 0.1% 
in H2O  
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2.10 Assessment of the transcriptome 
HUVECs at 80 % confluency were treated with equipotent concentrations of 60 nM MiuA, 
120 nM Jaspla, 20 nM ChivoA or 250 nM LatB respectively for 4 h. The concentrations were 
chosen in order to stay below levels causing visible alterations of cell morphology and 
overall actin structure. Samples for transcriptome analysis were prepared by F. 
Gegenfurtner. Transcriptome analysis was performed by Prof. Dr. Wolfgang Enard 
(Department Biology II, Ludwig-Maximilians University Munich, Germany). 
2.11 Quantification and statistical analysis 
Quantitative data are expressed as mean ± SEM. Statistical analysis was performed using 
the software GraphPad Prism Version 7.02 (GraphPad Software, Inc., La Jolla, CA, USA). 
Statistical differences were evaluated by using Kruskal - Wallis test or one-way analysis of 
variance (ANOVA). P-values lower than 0.05 were considered to be significant. For all tests, 
three independent replicates (n = 3) were used respectively. Specific information on the 
statistical procedures used can be found in the respective figure legends.  
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3.1 Miuraenamide A induces actin nucleation and polymerization, 
as well as stabilization of filaments 
Based on previous findings[38], we investigated the molecular mechanism of the interaction 
of miuraenamide A with actin alone. First, we examined the effect of Miuraenamide A on 
the actin polymerization process in a pyrene assay. With 1 μΜ Miuraenamide A, actin 
nucleation and polymerization were faster (Fig. 3.1A) but, interestingly, peak fluorescence 
was lower. This might result from substrate consumption by the rapid formation of small 
actin aggregates. Monitoring actin filament assembly by TIRF microscopy showed that 
Miuraenamide A increased the overall rate of formation of actin filaments (Fig. 3.1B). This 
increase in the number of filaments formed over time suggested a stabilizing effect during 
nucleation.  
Next, we investigated the influence of Miuraenamide A on the rate of actin filament 
elongation using TIRF microscopy. In the absence and presence of 250 nM of 
Miuraenamide A, we monitored the length of individual filaments as a function of time and 
found that the elongation rate doubled compared to control samples (Fig. 3.1C). To 
determine whether Miuraenamide A plays any role in stabilizing actin filaments, we 
monitored the disassembly of labeled actin filaments in the presence and absence of 5 μM 
Miuraenamide A by TIRF microscopy. As expected, the length of actin filaments decreased 
in a time-dependent manner in the absence of Miuraenamide A. In the presence of 
Miuraenamide A, disassembly of filaments was retarded (Fig. 3.1D). These results indicate 
that the binding of Miuraenamide A promotes both, the assembly and stabilization of actin 
filaments. 
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Figure 3.1 Miuraenamide A enhances actin polymerization and nucleation, and inhibits 
depolymerization 
(A) The pyrene assay shows an accelerated polymerization of actin after treatment with 
Miuraenamide A. (B) The TIRF assay shows increased number of filaments indicating more 
nucleation of actin upon addition of Miuraenamide A. (C) Actin elongation measured using TIRF 
microscopy. Left panel: Representative time series of fluorescence images show the elongation of 
actin filaments. Right panel: The calculated actin elongation rate. (D) Miuraenamide A reduces actin 
depolymerization as shown by TIRF microscopy. Left panel: Representative fluorescence images at 
different time points during F-actin depolymerization. Right panel: The average length of actin 
filaments was quantified as depolymerization parameters. Scale bars in (B) and (D) represent 15 µm. 
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Scale bar in (C) represents 5 µm. (Kruskal–Wallis test with Dunn’s test as post hoc, **P<0.01 vs. 
control, n=3).  
3.2 Miuraenamide A competes with phalloidin for binding to F-
actin 
Phalloidin is a well-known F-actin stabilizing compound with a well characterized binding 
site[49]. To investigate whether Miuraenamide A binding to actin competes with phalloidin 
binding, we performed a competition assay with rhodamine-labeled phalloidin. Rhodamine-
labeled phalloidin could be displaced from actin filaments by Miuraenamide A in a 
concentration dependent manner (Fig. 3.2A) with an IC 50 of about 5 nM (Fig. 3.2A-right 
panel). This indicates that Miuraenamide A may share a proximal binding site with phalloidin 
on F-actin, or that Miuraenamide A allosterically influences binding of phalloidin.   
3.3 Effect of Miuraenamide A on actin filament branch formation 
Subsequently, we measured the effects of Miuraenamide A on actin filament dynamics, 
which is more complex but also more physiologically relevant. First, we studied Arp2/3-
mediated actin filament nucleation. The actin-related protein Arp2/3 complex is a key actin 
filament nucleation factor that binds to actin and rapidly assembles distinctive branched 
filament networks. Addition of Miuraenamide A enhanced the overall polymerization in the 
presence of activated Arp2/3 (i.e. Arp2/3 in complex with the VCA domain of the WAVE 
protein) (Fig. 3.2C, upper panel). To visualize the effect of Miuraenamide A on actin Arp2/3-
mediated branch formation, we used TIRF to measure Atto488 labeled actin in the presence 
of Arp2/3 (activated by the VCA domain of the WAVE protein). The formation of branched 
filament networks is accelerated by an increasing concentration of Miuraenamide A (500 
nM, 1 μM). At 5 μM Miuraenamide A, a large number of actin nuclei were observed with 
very few branches (Fig. 3.2B, bottom panel). We made a similar observation in the pyrene 
assay: in the presence of 50 mM potassium, actin steadily polymerized, resulting in a linear 
growth curve. Addition of Arp2/3 complexes induced a sigmoidal curve of nucleation and 
polymerization. In the presence of an excessive concentration of Miuraenamide A (50 µM), 
the onset of actin nucleation was so fast that it could not be substantially accelerated by the 
addition of Arp2/3 complexes (Fig. 3.2C, lower panel). 
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Figure 3.2 Miuraenamide A competes with phalloidin for binding to F-actin and increases 
branch formation induced by Arp2/3 and CST-VCA 
(A) Miuraenamide A competes with phalloidin binding to actin filaments. Labeled F-actin was 
incubated with 16.5 nM rhodamine phalloidin and increasing concentrations of Miuraenamide A. 
Images of actin filaments were taken by TIRF microscopy. Left panel: TIRF images showing the 
Atto488-labeled actin filaments (upper panels) and rhodamine-labeled phalloidin (lower panels). At 
increasing concentrations of Miuraenamide A, the binding of phalloidin to actin filaments decreased. 
Right panel: The IC50 of Miuraenamide A was calculated (n=3). (B) Actin branch formation was 
triggered by addition of the Arp2/3 complex and GST-VCA during polymerization, and the process of 
branch formation was measured using TIRF microscopy. The representative time series of 
fluorescence images show actin branch formation. Red inserts: zoom-ins of single actin nuclei at 2× 
magnification.  (C) The results of pyrene assays show the fast nucleation induced by 5 µM 
Miuraenamide A and Arp2/3/VCA. Scale bar in A and B represents 15 µm. 
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3.4 Miuraenamide A inhibits proliferation of endothelial cells at 
nanomolar concentration and leads to actin aggregation 
To assess the effect of Miuraenamide A on cells, we first measured proliferation. At 
nanomolar concentrations, Miuraenamide A inhibited the proliferation of HUVEC cells with 
an IC 50 value of around 9 nM (Fig. 3.4A), which is comparable to that in tumor cell lines 
(HCT116, HepG2, HL-60, U-2OS)[41]. Phalloidin staining of F-actin revealed that one hour 
of incubation with 30 nM of Miuraenamide A reorganizes the actin cytoskeleton into clusters 
or aggregates (Fig. 3.4B). At 100 nM Miuraenamide A, the actin cytoskeleton was 
completely destroyed and perinuclear actin aggregates were observed (Fig. 3.4B). 
3.5 Miuraenamide A inhibits HUVEC cell migration 
To examine the effect of Miuraenamide A on the ability of cells to migrate, we performed a 
scratch assay. The migration of HUVEC cells was inhibited by Miuraenamide A in a 
concentration-dependent manner with an IC 50 of approximately 80 nM (Fig. 3.4C). Since 
migration normally occurs in a gradient of growth factors, we studied the effect of 
Miuraenamide A on the chemotactic properties of HUVECs. In a 2D-chemotaxis assay, the 
directed migration of HUVECs was inhibited by 10 nM Miuraenamide A, as seen by the 
reduction of the forward migration index (FMI) and directness, while the mean velocity of 
movement was not affected (Fig. 3.4D). In 3D-chemotaxis, at 10 nM Miuraenamide A, cell 
migration directness, mean velocity and FMI were all significantly reduced (Fig. 3.4E). 
These results indicate that Miuraenamide A has an overall effect on both cell motility and 
directionality of the movement, both in a simple 2D and in more physiological 3D 
environments. The reduced velocity in the 3D system could be explained by the cells having 
a reduced ability to squeeze through a small meshwork.  
Overall, the cellular response to Miuraenamide A was typical for actin nucleating 
compounds[50]. 
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Figure 3.3 Miuraenamide A inhibits proliferation of HUVEC cells, induces actin aggregation 
and inhibits migration 
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(A) Half inhibitory concentration (IC 50) on proliferation of Miuraenamide A (n=3). (B) HUVEC cells 
were treated with the indicated concentrations of Miuraenamide A for 1 h, fixed and stained for F-
actin (red) and DNA to highlight the nuclei (blue). Representative images out of 3 independent 
experiments performed in triplicates are shown. The upper scale bar in (B) represents 75 µm, and 
the lower scale bar represents 30 µm. The white frame indicates the zoomed in area. (C) Confluent 
HUVECs were scratched and treated with Miuraenamide A (indicated concentrations). After 16 h, 
images were collected and the cell covered area was analysed. Left panel: the measured IC 50 of 
Miuraenamide A from a scratch assay is shown (n=3). Right panel: Representative images of the 
scratch assay. The scale bar represents 200 µm. Miuraenamide A inhibits endothelial cells migration 
(D) in 2D- and (E) in 3D-chemotaxis assays. Quantitative evaluation of the parameters X-Forward 
migration index, directness and mean velocity are shown (n=3). Analysis of one representative 
experiment (out of triplicates in three independent experiments) is shown. (Kruskal– Wallis test with 
Dunn’s test as post hoc, *P<0.05, **P<0.01 vs. control, n=3). 
3.6 Effect of Miuraenamide A on HUVECs tube formation 
To study the effect of Miuraenamide A on a morphogenetic process in vitro, a tube formation 
assay on matrigel was performed. The tube structure when compared with control could not 
be established after 16 – 20 h incubation with increasing concentration of Miuraenamide A 
(Fig. 3.5A). The maturation of the network, which is characterized by a reduction of 
branching points, tube loops and tube number, as well as by an increase of tube length in 
control, did not occur after treatment with 10 nM and 30 nM Miuraenamide A (Fig. 3.5B). 
Treatment led to a fragmented phenotype of the tubular network with a higher number of 
shorter tubes. At 100 nM Miuraenamide A, HUVEC cells could not build a network at all, the 
cell-cell contacts were clearly disrupted. Thus, Miuraenamide A interferes with the stability 
of tubes and development of cell-cell contacts. 
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Figure 3.4 Miuraenamide A disturbs tube maturation of endothelial cells on Matrigel 
HUVECs were seeded on matrigel, treated with the indicated concentration of Miuraenamide A 
respectively and incubated for 16 h. Images were taken and analyzed. (A) Representative images in 
one experiment (out of triplicates in three independent experiments each) are shown. Cell covered 
areas recognized by software are indicated in blue, tubes are indicated in pink, and loops are 
indicated by yellow numbers. (B) Tube length, number of total loops, total tubes, and total branching 
points were analyzed (n=3). The scale bar represents 30 µm. (One-way ANOVA with Tukey post hoc 
test for multiple comparisons, *P<0.05 vs. control, n=3). 
3.7 Effect of Miuraenamide A on the binding of proteins to G-
actin 
We next investigated whether Miuraenamide A affects the binding of ABPs to G-actin. To 
this end, we performed pulldown experiments with G-actin immobilized on beads and added 
single ABP (gelsolin, profilin, cofilin or Arp2/3 complex with GST-VCA). As depicted in Fig. 
3.6A-D, the total amount of the tested ABPs in G-actin pellets did not increase or decrease 
even if treated with a high amount of Miuraenamide A (10 or 100-fold excess), indicating 
that Miuraenamide A does not compete with gelsolin, profilin, cofilin or Arp2/3 complex for 
binding to G-actin. 
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Figure 3.5 Miuraenamide A does not change the binding of ABPs to G-actin 
G-actin beads were incubated with indicated concentrations of Miuraenamide A for 30 min at room 
temperature, then 0.01mg/ml of the G-actin binding proteins (A) gelsolin, (B) profiling, (C) cofilin and 
(D) Arp2/3 complex & GST-VCA was added respectively and incubated for 1 h at room temperature. 
After 1 h, the mixture of actin beads and ligands was spun and only the ligands bound to G-actin will 
be co-precipitated in the pellet. The amount of G-actin binding protein in the pellets was quantified. 
Representative images of protein bands and quantifications are shown. (Kruskal–Wallis test with 
Dunn’s test as post hoc, no significant differences vs. control, n=3). 
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3.8 In contrast to jasplakinolide, Miuraenamide A influences 
cofilin binding to F-actin 
To investigate potential competition of Miuraenamide A and ABPs for binding to F-actin, we 
also performed a binding assay with cofilin, gelsolin and Arp2/3 complex (together with 
GST-VCA) to F-actin. In the absence of Miuraenamide A, cofilin was largely found in the F-
actin pellet (Fig. 3.7A), as expected from the known interaction between cofilin and F-actin. 
In the presence of Miuraenamide A, a significant reduction of cofilin was observed in the 
pellet (Fig. 3.7A, upper panel). Jasplakinolide did not change binding of cofilin to F-actin, 
even when added at a ten-fold concentration in comparison to Miuraenamide A. (Fig. 3.7A, 
lower panel). Neither Miuraenamide A, nor jasplakinolide influenced binding of gelsolin (Fig. 
3.7B), and Miuraenamide A did not affect Arp2/3 complex binding to F-actin, since the 
amounts of Arp2/3 complex in F-actin pellet were similar in the presence or absence of 
Miuraenamide A (Fig. 3.7C). These results suggest that Miuraenamide A selectively 
interferes with the binding of cofilin to F-actin, and that this action is specific for 
Miuraenamide A, since it was not mimicked by jasplakinolide. 
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Figure 3.6 Miuraenamide A selectively inhibits binding of cofilin to F -actin 
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(A) Miuraenamide A inhibits binding of cofilin to F-actin filaments (upper panel), while jasplakinolide 
does not (lower panel). F-actin was incubated with (A) cofilin, (B) gelsolin or (C) Arp2/3 complex & 
GST-VCA, together with Miuraenamide A or jasplakinolide (molar ratio 1:10). Binding of gelsolin (B) 
or Arp2/3 (C) to F-actin were not influenced by Miuraenamide A or jasplakinolide. The amount of F-
actin binding protein in the total sample, supernatant and pellets was quantified. Representative 
images of protein bands and quantifications are shown. (Kruskal–Wallis test with Dunn’s test as post 
hoc, **P<0.01 vs. control, n=3). 
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4.1 Chivosazole A sequesters G-actin, inhibits actin nucleation, 
polymerization and branch formation and destabilizes F-actin 
in vitro 
To characterize the functional effects of chivosazole A in comparison with a prototypic actin 
depolymerizer with a different binding site and mode of action (latrunculin B), we performed 
a pyrene assay with pyrene labeled actin and TIRF assay with Atto488 labeled actin. In the 
pyrene assay, chivosazole A concentration dependently inhibits actin polymerization (Fig. 
4.1A), as previously described by others[44]. When investigating the underlying 
mechanisms, we found that the critical concentration of actin in the presence of either 
latrunculin B or chivosazole A, was increased to a similar degree (Fig. 4.1B). This indicates 
a similar sequestering action of both compounds. Accordingly, we found a decreased 
nucleation of actin in TIRF assays (Fig. 4.1C), and a lower rate of polymerization (Fig. 4.1D). 
In addition, we observed a destabilizing effect of chivosazole A on F-actin filament stability 
(Fig. 4.1E). In addition, we observed the formation of branched filament networks triggered 
by Arp2/3 complex and GST-VCA. Branches formed slower and shorter with 5 μM 
chivosazole A (Fig. 4.1F). Taken together, our data suggest that chivosazole A inhibits actin 
filament branch formation by sequestering G-actin, so that less actin nuclei were formed for 
forming actin filament branches.  
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Figure 4.1 Chivosazole A sequesters G-actin, inhibits actin nucleation, polymerization and 
branch formation and destabilizes F-actin in vitro 
(A) Chivosazole A inhibits polymerization of pyrene actin concentration dependently. (B) Chivosazole 
A (20 µM) and Latrunculin B (positive control, 20 µM) shift the critical concentration of actin for 
polymerization to a similar degree. (C) and (D) In TIRF assays, chivosazole A inhibits nucleation of 
actin and the elongation rate. (E) F-actin filaments are destabilized by chivosazole A in the TIRF 
assay. (F) Actin branch formation is triggered by addition of the Arp2/3 complex and GST-VCA during 
polymerization, and the process of branch formation is inhibited by chivosazole A. The representative 
time series of fluorescence images are shown. Red inserts in (F): Zoom-ins of single actin nuclei at 
2× magnification. Scale bars in (C), (E) and (F) represent 15 µm. Scale bars in (D) represents 5 µm. 
Data are presented as mean ± SEM, n = 3, *p < 0.05 using Kruskal-Wallis test. 
4.2 Chivosazole A inhibits proliferation and changes actin 
architecture in endothelial cells 
In order to get insights into potential functional differences between the two compounds (in 
spite of their similar actions on actin alone), we performed comparative experiments on a 
cellular level. In HUVECs chivosazole A inhibited proliferation with an IC 50 of approximal 
3 nM. This is in good accordance with previously published values in different mammalian 
cells[44], and demonstrates chivosazole A to be much more potent than latrunculin B (Fig. 
4.2A). Morphologically, chivosazole A causes dissociation of F-actin fibers and formation of 
amorphous actin aggregates with increasing concentrations (Fig. 4.2B).  
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Figure 4.2 Chivosazole A inhibits proliferation and changes actin architecture in endothelial 
cells 
(A) Chivosazole A (left panel) inhibits HUVEC cells proliferation much more potently than latrunculin 
B (right panel). (B) The actin cytoskeleton of HUVECs is rapidly rearranged by chivosazole A. 
Representative images in one experiment (out of triplicates in three independent experiments each) 
are shown. Lower panel: Zoom-in of the white frames indicated as boxes in the upper panels. Blue: 
nuclei stained with Hoechst, red: F-actin stained with rhodamine-phalloidin. Scale bars: 75 µm (upper 
panel), 30 µm (lower panel). 
4.3 Chivosazole A inhibits HUVEC cell migration  
Since cellular motility is a central aspect of actin function, we investigated the effects of the 
two compounds on migration of HUVECs in a scratch assay and specifically on directional 
migration (chemotaxis). The IC 50 value concerning migration was 10-fold higher than for 
proliferation (Fig. 4.3A). This is most likely due to the shorter duration of the migration assay 
(16 h vs. 72 h). With latrunculin B the difference in potency in comparison to chivosazole A 
was less in migration than in proliferation, indicating that latrunculin B loses potency over 
time more rapidly than chivosazole A. In 2D-chemotaxis assay, overall features of cell 
motility (velocity), and directional components of migration were assessed. Both 
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compounds caused a decrease of cell velocity, and, additionally, a loss of the “sense of 
direction” (Fig. 4.3B).  
 
 
Figure 4.3 Chivosazole A inhibits migration in endothelial cells 
(A) Upper panel: Dose response curves of cell migration after treatment with chivosazole A or 
latrunculin B in a scratch assay. Lower panel: representative images of scratches after migration. 
Scale bar: 200 µm. (B) In 2D-chemotaxis assay, quantitative evaluation of the parameters X-Forward 
migration index, directness and mean velocity are shown. Analysis of one representative experiment 
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(out of triplicates in three independent experiments) is shown. Data are presented as mean ± SEM, 
n = 3, *p < 0.05, **p < 0.01 using Kruskal-Wallis test. 
4.4 Chivosazole A disturbs tube formation in endothelial cells 
To study the effect of chivosazole A on a morphogenetic process in vitro, a tube formation 
assay on matrigel was performed. The tube structure when compared with control could not 
be established after 16 – 20 h incubation with either chivosazole A or latrunculin B (Fig. 4.4). 
Treatment led to a fragmented phenotype of the tubular network with a higher number of 
shorter tubes. The cell-cell contacts were disrupted. Thus, chivosazole A has same effect 
as latrunculin B, interfering with the stability of tubes and development of cell-cell contacts. 
 
Figure 4.4 Chivosazole A disturbs tube formation in endothelial cells 
(A) HUVECs were seeded on matrigel, treated with the indicated concentration of chivosazole A and 
latrunculin B respectively and incubated for 16 h. Images were taken and analyzed. Representative 
images in one experiment (out of triplicates in three independent experiments each) are shown. Cell 
covered areas recognized by software are indicated in blue, tubes are indicated in pink, and loops 
are indicated by yellow numbers. The scale bar represents 30 µm. 
4.5 Chivosazole A competes with ABPs for binding to G-actin 
and causes dimerization of actin 
Based on the surprising functional differences between the two compounds concerning 
transcription (Table S6, S7 and S8), and the fact that actin influences transcriptional 
regulation mainly by its interaction with ABPs, we tested the effects of the two compounds 
on the binding of several proteins (cofilin, gelsolin and profilin) to G-actin. We performed an 
actin pull-down assay with G-actin immobilized on beads and single ABPs in the absence 
and presence of chivosazole A or latrunculin B, then quantified the ABP binding to G-actin. 
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As seen in Fig. 4.5A-C (left panels), the total amount of the tested ABPs in G-actin pellets 
decreased with chivosazole A (molar ratio 1:100), indicating that it prevented binding of 
cofilin, gelsolin and profilin to G-actin. In contrast, latrunculin B had no such effect (Fig. 
4.5A-C, right panels), which offers a potential explanation for the functional differences 
between these two compounds.  
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Figure 4.5 Chivosazole A prevents the binding of ABPs to G-acin, while latrunculin B does 
not 
G-actin beads were pretreated with indicated concentrations of either chivosazole A or latrunculin B 
for 30 min at room temperature, then co-incubated with the G-actin binding proteins (A) cofilin, (B) 
gelsolin or (C) profilin at a molar ratio of 100:1 (compound: ABP). After 1 h, the mixture of actin beads 
and ligands was spun and only the ligands bound to G-actin will be co-precipitated in the pellet. The 
amount of ABP in pellet was quantified. Representative images of protein bands are shown. Data 
are presented as mean ± SEM, n = 3, *p < 0.05, **p < 0.01 using Kruskal-Wallis test. 
 
Since the binding affinity of thymosin β4 is very weak, and we were not able to detect this 
protein in the pull-down assay, we crosslinked the bound protein as previously 
described[51]. With crosslinking, a 1:1 complex of thymosin β4 with G-actin at 
approximately 47.5 kDa is detectable (Fig, 4.6A, left panel). Chivosazole A reduced 
crosslink product formation (Fig. 4.6A, right panel). In addition, a high molecular weight 
complex (approximately 100 kDa) was formed in the presence of chivosazole A (Fig. 4.6A, 
left panel and also in the absence of thymosin β4, Fig. 4.6C), suggesting the formation of 
G-actin dimers. Latrunculin B decreased the formation of the thymosin β4/G-actin complex 
(Fig. 4.6B), but did not cause formation of actin dimers. Gel filtration experiments also 
showed an increase of actin dimers in the presence of chivosazole A under conditions of a 
different pH (Fig. 4.6D, experiments were performed by Dr. Sabine Schneider, Department 
of Chemistry, Technical University of Munich, Germany). However, the retention time of 
these dimers differs from that of spontaneously formed physiological dimers, indicating a 
different structure (Fig. 4.6D).  
4 Results Part 2 : Chivosazole A modulates protein-protein-interactions of actin 
 
51 
 
Figure 4.6 Chivosazole A prevents thymosin β4 binding to G-actin, and causes formation of 
unphysiological actin dimers 
(A) This interaction was inhibited by chivosazole A. In the presence of chivosazole A actin dimers 
(~100 kDa, the boxed-in portion of protein bands) formed. (B) Binding of thymosin β4 to G-actin was 
also inhibited by latrunculin B, however, no actin dimers were formed in the presence of this 
compound.  (C) The actin dimers formed by chivosazole A were not dependent on the presence of 
thymosin β4. Representative images of protein bands and quantitative densitometric analyses are 
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shown. (D) Size-exclusion chromatography at different pH values indicate the formation of actin-
dimers in the presence of chivosazole A. Dimers formed spontaneously in the absence of 
chivosazole A elute at a time point different from the drug induced ones, hinting at an unphysiological 
conformation of the latter ones. Results of size-exclusion chromatography in (D) are provided by Dr. 
Sabine Schneider, Department of Chemistry, Technical University of Munich, Germany. (Data are 
presented as mean ± SEM, n = 3, *p < 0.05 using Kruskal-Wallis test) 
 
Chivosazole F, a derivative which is structurally very similar to chivosazole A, and 
rhizopodin, an also structurally related compound, inhibited binding of profilin, gelsolin and 
cofilin to G-actin to a similar degree as chivosazole A (Fig. 4.7). 
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Figure 4.7 Chivosazole F and rhizopodin both compete with (A) cofilin, (B) gelsolin and (C) 
profilin binding to G-acin 
G-actin beads were pretreated with either chivosazole F or rhizopodin for 30 min at room temperature, 
then co-incubated with each ABP at a molar ratio of 10:1 and 100:1 (compound: ABP). After 1 h, the 
mixture of actin beads and ligands was spun and only the ligands bound to G-actin will be co-
precipitated in the pellet. The amount of ABP in pellet was quantified. Representative images of 
protein bands are shown. Data are presented as mean ± SEM, n = 3, *p < 0.05, **p < 0.01 using 
Kruskal-Wallis test. (D) Chemical structure of rhizopodin adapted from Patocka J et al. 2017. 
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5.1 Actin targeting compounds: promising biological tools and 
therapeutic options  
Actin is the most abundant protein in eukaryotic cells and the protein with the greatest 
variety of binding partners[3, 52, 53]. Due to its ubiquitous expression and its many 
biological functions, actin has not been pushed as a clinically relevant drug target. 
Especially the question how selective functional effects could be elicited by just increasing 
or decreasing overall actin polymerization by the use of small molecular binders has 
precluded the use of actin targeting natural compounds in a therapeutic setting for many 
years in spite of their availability[28, 30, 54]. In recent years, however, it has become 
increasingly clear that actin-binding proteins (ABPs) are the key to localized and specific 
regulation of actin polymerization and depolymerization. For example, it has been shown 
that JMY or WHAMM are needed to localize actin nucleation specifically to the 
autophagosome[55, 56]. Since the amount of G-actin in a cell is limited, a competition 
between actin monomers, F-actin filaments, and ABPs for binding to the available G-actin 
pool takes place, and turns out to be relevant for regulation of actin function[31, 52, 57]. 
Exploiting this level of regulation by using the concept of “biomolecular mimicry”[34, 58] 
would open a new field of biological tools or even therapeutic options by developing novel 
and much more specific actin targeting compounds. 
5.2 Miuraenamide A, a novel actin stabilizing compound, 
selectively inhibits cofilin binding to F-actin 
5.2.1 Miuraenamide A, an actin stabilizer, and its specific mode of binding 
Miuraenamide A has been discovered in 2006 with high cytotoxicity to a range of tumor cell 
lines[41]. It is presumed to be an actin filament stabilizing agent[38]. The absolute 
stereostructure of miuraenamide A was determined soon in 2008[40]. Comparable 
biological effects were observed with other cyclodepsipeptides, such as chondramide[42] 
and jasplakinolide[35], which is not surprising on the basis of their closely related structure 
(Fig. 1.1). However, it is still poorly characterized and its influence on actin is still not clear. 
In this study, we have performed an in-depth characterization of miuraenamide A. The in 
vitro data on isolated actin indicate that miuraenamide A has a profile similar to phalloidin 
or jasplakinolide (increase of nucleation, enhanced polymerization, and stabilization). FCS 
assay result suggests that miuraenamide A favors polymerization by stabilizing the early 
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stage oligomers formed during nucleation (Fig. S1 and Fig. S2). This reveals the increasing 
nucleation and elongation effect of miuraenamide A in TIRF assay (Fig. 3.1). The 
competition with phalloidin for actin binding in the TIRF assay indicates binding sites of both 
compounds in close proximity (Fig. 3.2A).  
To get an impression of the specific binding mode of miuraenamide A, we performed in 
silico studies (experiments were performed by the group of Prof. Iris Antes, Protein 
Modelling group, Technical University of Munich, Germany), which revealed that 
miuraenamide A binds to motifs similar, but different to the binding site of phalloidin, 
chondramide, or jasplakinolide[59-61]. Interaction of a compound with F-actin is complex, 
since the compound may bind to three actin molecules at the same time at different sites. 
For the sake of simplicity, we collapsed all binding sites of miuraenamide A, phalloidin and 
jasplakinolide on one actin monomer, respectively (Fig. S3). This simulation reveals that M4 
is a binding site which miuraenamide A shared with phalloidin and jasplakinolide, which in 
part explains the competition of Miuraenamide A with phalloidin. M2 and M5 also show 
similar binding sites as phalloidin and jasplakinolide, but M1 and M3 address sites on the 
actin molecule, which are not bound by phalloidin or jasplakinolide. The mode of binding to 
M1 is unique in that the bromophenol substitution of the macrocycle and the three aromatic 
residues from actin (Tyr133, Phe352, and Tyr143) form an aromatic cyclic tetramer (Fig. 
S4A and B). Similar motives (involving more or less aromatic cycles) were shown to be 
frequently observed in proteins and contribute to the stabilization of their tertiary 
structure[62-64]. They were also recently identified as a key feature of metal centered 
cycloadducts[65]. This relatively strong interaction reveals the importance of the 
bromophenol ring as a crucial moiety of the macrocyclic miuraenamide A. The second 
phenyl ring bound to the macrocycle, on the other hand, is not engaged in any crucial 
interactions.  
Analysis of the influence of miuraenamide A binding on the F-actin filament structure by 
simulation of actin-trimer complexes with and without bound miuraenamide A showed that 
the binding of miuraenamide A influences the overall structures of the actin timer, as for the 
apo-actin-trimer a different relative arrangement of the individual actin monomers was 
observed compared to the holo-trimer complex (Fig. S4C, D, E and F). A more detailed 
analysis of the structures (Fig. S4G and Fig. S5A) reveals that the miuraenamide A ligand 
bound to the actin DNAse I binding site triggers the migration of the D-loop in monomer 3 
towards actin. This phenomenon increases the contact area between the monomers. 
Presumably miuraenamide A further acts as a buffer between these two monomers and 
stabilizes the compact trimer form. Comparisons between holo- and apo-structures show 
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that the interaction between monomers 2 and 3 is affected most by the binding of 
miuraenamide A (Fig. S4D, F, blue lines), although all monomers contain a ligand in the 
holo-system. This is consistent with the fact that only the ligand of monomer 2 is located at 
an inter-monomeric interface in the trimer simulation. This observation, together with the 
RMSD analysis, further highlights that the binding of miuraenamide A does not affect the 
individual integrity of the units but regulates the inter-monomeric interactions. Overall, 
miuraenamide A binding ensures a tighter and stronger packing of the actin monomers 
compared to the apo F-actin (Fig. S4H) by shifting the D-loop, which is indispensable for F-
actin stabilization[59].  
5.2.2 Miureanamide A has comparable effect on a cellular level as other actin 
stabilizer, but has a unique selectivity inhibition on cofilin binding to F-actin 
To find out, whether this unique binding mode results into a different functional outcome, 
we investigated miuraenamide A also on a cellular level. Miuraenamide A had functional 
effects similar to chondramide, another actin nucleator (inhibition of proliferation, migration), 
and also the morphological changes were comparable[42, 66].  
Since the hydrophobic cleft in the actin molecule, where M1 is situated, is the main hub for 
interaction of actin with other proteins, we analyzed interactions of ABPs with both, G- and 
F-actin. Interactions of ABPs with G-actin were not altered by miuraenamide A. Obviously, 
the compound does not bind to a single monomeric actin, or it does not directly interfere 
with protein binding. In contrast, we observed that miraenamide A inhibited ABP cofilin 
binding to F-actin. The interesting point here is that this observation was specific for cofilin 
– the binding of gelsolin or the Arp2/3 complex on F-actin were not affected. Even more 
interestingly, jasplakinolide did not have this effect. Consequently, the action of 
miuraenamide A seems to be due to its unique binding mode. Our molecular dynamics (MD) 
simulations offer an explanation for the inhibition of cofilin binding to F-actin by 
miuraenamide A: the shift of the D-loop by miuraenamide A leads to a clash between this 
loop and cofilin in its bound conformation (Fig. S5B).  
It has already been sporadically described that actin binding compounds are able to 
influence binding of ABPs to G- or F-actin (e.g. cytochalasin D and MRTF[33, 67], or 
phalloidin and gelsolin[68]). Obviously, these small molecules can act as inhibitors of 
protein-protein interactions, and afford a certain specificity.  
On a functional cellular level, the comparison between jasplakinolide and miuraenamide A 
was quite astounding. Though migration and proliferation were inhibited by miuraenamide 
A as was to be expected, the differences of transcriptional regulation in HUVEC cells after 
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treatment with both compounds were pronounced: 101 genes were regulated in a 
significantly different way (Table S1 and S3). When the regulated genes are classified into 
functionally relevant gene ontologies (Table S4 for Miuraenamide A and Table S5 for 
jasplakinolide), it becomes clear that most of the differences between Miuraenamide A 
treatment and jasplakinolide do not result from different extents of regulation of the same 
genes, but from regulation of different sets of genes (Table S2). This might be linked to the 
effects of miuraenamide A on binding of cofilin to F-actin (Fig.5.1), since cofilin directly 
modulates nuclear architecture[69], but also plays an important role in regulating nuclear 
actin levels[70], which, in turn, have an influence on transcriptional regulation[71]. However, 
due to the complexity of the role of actin and ABPs in transcriptional regulation, we cannot 
rule out other modes of action of miuraenamide A treatment.  
 
 
Figure 5.1 MiuA prevents cofilin binding to F-actin 
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5.3 Chivosazole A modulates protein-protein-interactions of actin 
5.3.1 Is chivosazole A just another of many known natural compounds, which 
interfere with actin polymerization dynamics? 
Chivosazole A has been initially described as cytotoxic agent in eukaryotic cells in 1995[43], 
and its absolute configuration has been resolved 12 years later[45]. Its actin interfering 
effects (inhibition of G-actin polymerization and depolymerization of F-actin) were identified 
2009[44]. One could argue that chivosazole A is just another of many known natural 
compounds, which interfere with actin polymerization dynamics[72]. However, it turned out 
that each of these actin binding compounds has unique functional features, and that it is 
worthwhile to study their structure-activity-relationships.  
Very recently, chivosazole F, a compound closely related to chivosazole A has been shown 
to directly interact with actin by chemoproteomics[73]. Based on genome-wide mutagenesis 
studies in yeast with chivosazole F it was proposed that the binding site for chivosazole F 
on actin would partially overlap the binding site for latrunculinA in the ATP-binding cleft [73]. 
However, here we present a crystal structure of an actin- ChivoA complex, revealing that it 
binds at the barbed end of actin, and not to a site close to the latrunculin A binding site. This 
discrepancy could be explained by the fact that we used chivosazole A, while chivosazole 
F was used in the other work. However, this seems unlikely, as both compounds are nearly 
identical (Fig. 1.2). It is feasible that the sequence of actin (which is evolutionary highly 
conserved) lacks flexibility, and mutations at the real binding site just do not yield functional 
protein. The described mutations (R183K and R335K) might have allosteric consequences, 
influencing binding of chivosazole F at a distant site[73].  
In order to elucidate the previously unknown binding mode of chivosazole A to actin, we 
first determined the X-ray crystal structure of chivosazole A in complex with G-actin to 2.4 
Å resolution (experiments were performed by Dr. Sabine Schneider, Department of 
Chemistry, Technical University of Munich, Germany). Chivosazole A binds to the barbed 
end (target binding cleft) of G-actin (Fig. S6A and Fig. S7). This binding site for chivosazole 
A is very close, but not identical to those of many actin binding macrolides (Fig. S6B): 
Despite the variation in ring size and decoration of the tail with different backbone 
substitutions present in actin-binding macrolides, they possess a common theme in their 
interaction with actin. In all reported actin complex-structures the macrolactone ring binds 
to subdomain 1, with the side chain/tail protruding into the hydrophobic cavity between 
subdomain 1 and 3[34, 74-81]. The oxazole ring of chivosazole A occupies an intermediate 
5 Discussion 
 
60 
position compared to the trisoxazole rings of jaspisamide A, kabiramide C and ulapulaide 
A[34, 81] (Fig. S6B). Albeit we cannot rule out that crystal lattice contacts impact on the 
binding mode of chivosazole A (Fig. S7), for jaspisamide A and kabiramide C identical 
interactions with actin were observed in structures obtained from different crystal 
symmetries.  
Interestingly, the binding side of chivosazole A overlaps with that for a number of actin-
binding proteins (ABPs). This might explain, why chivosazole A competes with cofilin, 
gelsolin, profilin or thymosin β4 for binding to G-actin, while latrunculin B does not. These 
proteins interact with actin by insertion of an amphiphilic helix into the target binding cleft 
as depicted in Fig. S8 [82-86].  
Recently the cryo-EM structure of F-actin has been reported (PDB code 6BNO[87]), 
revealing an interface of 1,076 Å2 between the actin-monomers (theoretical gain of free 
energy of -6.9 kcal/mol). Here the D-loop (residue 40-50) slides into the target binding cleft 
between subdomain 1 and 3. Superposition of the F-actin structure and the actin-ChivoA 
complex shows that the ChivoA-tail partly occupies the binding site for the DNase-binding 
loop (Fig. 6C), and, in addition, slightly perturbs other structural elements involved in actin-
actin interaction (Fig. S6C). This explains the F-actin-severing effect of chivosazole A, which 
does not occur with rhizopodin or cytochalasin D, other actin binding polyketides[44, 88]. 
Albeit actin-ChivoA complexes can still form dimers in vitro, their overall shape differs from 
that of physiological actin-dimers in solution as indicated by size-exclusion chromatography 
(Fig. 4.6D). The occurrence of actin dimers has already been described with rhizopodin and 
swinholide A[78, 80]. However, these compounds have two enamide side chains each, 
which explain their crosslinking activity, while chivosazole A has just one. It has recently 
been shown that the induction of unphysiological actin oligomers by toxins can cause 
dramatically altered affinity towards ABPs[89]. This effect could further contribute to the 
higher efficacy of chivosazole A in comparison to latrunculin B. 
5.3.2 Chivosazole A selectively competes with ABPs 
Chivosazole A has been previously described to inhibit actin polymerization and to induce 
F-actin depolymerisation[44]. In our work, we corroborate this finding, and additionally show 
that nucleation is inhibited and G-actin is sequestered in a similar way as with latrunculin B. 
This makes it understandable that at first glance both compounds have similar functional 
effects on eukaryotic cells (proliferation, migration, cytoskeletal architecture), which can be 
explained by an overall disturbance of actin turnover. However, when having a closer look 
at binding of ABPs to G-actin, as discussed above, we see striking differences between 
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both compounds, and a high selectivity: profilin, gelsolin and cofilin compete only with 
chivosazole A (Fig.5.2), while chivosazole A and latrunculin B both compete with thymosin 
β4. Influencing these interactions might have distinct consequences on downstream 
signaling, and ultimately on gene expression. Indeed, we see the differences of chivosazole 
A and latrunculin B on gene expression in endothelial cells: a number of genes that are only 
up- or downregulated by chivosazole A and not by latrunculin B, and vice versa (Table S6, 
S7 and S8).  
 
 
Figure 5.2 ChivoA prevents ABPs binding to G-actin 
  
Consequently, our result reveals a previously unexpected layer of complexity in the 
mechanism of action of actin binding compounds: instead of just causing bulk stabilization 
or de-stabilization of actin fibers, distinct cellular functions could be preferentially addressed 
by single compounds. “Biomolecular mimicry”[58], the fact that compounds can selectively 
compete with ABPs, and the high structural diversity of actin binding compounds might team 
up to generate an unprecedented functional selectivity for pharmacologically targeting actin. 
Since the total synthesis of chivosazole F has been resolved[46], and chivosazoles can be 
produced biotechnologically, these compounds might be ideal candidates for derivatization 
and for exploring structure-activity-relationships with actin. 
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5.4 Summary and conclusion 
In our work we show that  
 
 Miuraenamide A has cellular effects and actin stabilizing effect in vitro comparable to 
jasplakinolide, owing to their closely related structure, 
 Chivosazole A has cellular effects and actin destabilizing effect in vitro similar to 
latrunculin B. 
 
 
 
Figure 5.3 Effect of actin binding compounds on actin dynamics 
Miuraenamide A induces actin nucleation, polymerization and stabilizes F-actin. Chivosazole A 
destabilizes F-actin, inducing actin depolymerization. 
 
However, we identified the unique mode of actions of both miuraenamide A and 
Chivosazole A by structural data that 
 
 Miuraenamide A selectively inhibits binding of cofilin to F-actin and causes 
transcriptional regulation different from that of jasplakinolide, 
 Chivosazole A competes with ABPs for binding to G-actin in contrast to latrunculin B, 
and influences transcriptional activity in human primary cells in a different manner from 
latrunculin B. 
 
Consequently, our findings reveal that small structural differences in actin binding 
compounds can cause functional selectivity (miuraenamide A and jasplakinolide), and the 
mechanisms of actions of actin binding compounds are much more complex than previously 
conceived which was not presumed in this class of molecules. The much better synthetic 
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accessibility of both miuraenamide A and chivosazole A, as compared to other actin binding 
compounds, makes them ideal candidates for studying structure-activity relationships. 
Ideally, it could be feasible to rationally create appropriate derivatives with improved 
activities that do not influence actin polymerization or depolymerization per se, but 
selectively modulate the binding of single ABP, and circumvent the selectivity issues, which 
hindered the development of actin-addressing drugs.  
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6.1 Part 1: Miuraenamide A, a novel actin stabilizing compound, 
selectively inhibits cofilin binding to F-actin 
Actin binding compounds such as phalloidin, jasplakinolide and latrunculin are widely used 
tools in cell biology regulating actin dynamics. Jasplakinolide is a prototypic actin stabilizer 
which binds to F-actin with no effect on ABPs (cofilin, gelsolin, profilin). In contrast 
miuraenamide A, as a new actin stabilizer, competes exclusively with cofilin for binding to 
F-actin. Notably, the molecular basis for this difference still remains to be determined. To 
investigate whether this difference is due to a specific binding site in miuraenamide A we 
performed molecular dynamics simulations. These simulations suggest that the 
bromophenol group of miurenamide A interacts with actin residues Tyr133, Tyr143, and 
Phe352. This interaction shifts the D-loop of the neighboring actin, creating tighter packing 
of the monomers, and blocks the binding site of cofilin.  We found that miuraenamide A 
shows activity similar to jasplakinolide both in vitro with respect to polymerization, 
depolymerization, branching, nucleation and in vivo with respect to cell proliferation, 
migration. However, gene expression in HUVEC cells was differentially affected by both 
compounds, indicating functional differences. We found that relatively small changes in the 
molecular structure give rise to this selectivity, suggesting that actin binding compounds 
might serve as promising scaffolds for creating actin binders with specific functionality 
instead of just “stabilizers”. 
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6.2 Part 2: Chivosazole A modulates protein-protein-interactions 
of actin  
Actin is a protein of central importance for many cellular key processes. Its function is 
regulated by local interactions with a large number of ABPs. To date, various compounds 
are known either increasing or decreasing polymerization dynamics of actin. However, no 
actin binding compound has been developed for clinical applications yet, due to selectivity 
issues. We provide a crystal structure of the natural product chivosazole A bound to actin, 
and show that – in addition to inhibiting nucleation, polymerization and severing of F-actin 
filaments – it selectively modulates binding of ABPs to G-actin: while unphysiological actin 
dimers are induced by chivosazole A, interaction with of gelsolin, profilin, cofilin and 
thymosin β4 is inhibited. Moreover, chivosazole A causes transcriptional effects differing 
from latrunculin B, an actin binder with a different binding site. Thus, our data show that 
chivosazole A and related compounds could serve as scaffolds for the development of actin 
binding molecules selectively targeting specific actin functions. 
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8.1 Supplementary Figures 
 
Figure S 1 Measurement of actin nucleation by Fluorescence correlation spectroscopy (FCS) 
experiment 
The fluorescence signal of 100 nM actin-atto488 as a function of time after 1h incubation, without (A) 
and with (B) 10 × excess of Miuraenamide A. (C) FCS curves of 100 nM actin-atto488 with and 
without Miuraenamide A. Inset: detail of the autocorrelation function at longer timescales showing 
the formation of larger oligomers with Miuraenamide A. (D) Number of spikes due to filaments 
diffusing through the observation volume in 10 min time intervals. The data show that up to 6 times 
more spikes are observed during the course of one hour in the presence of Miuraenamide A. Error 
bars represent the standard error of the mean of three independent measurements. (Results were 
provided by Prof. Dr. Don C. Lamb, Department Chemistry, Ludwig-Maximilians University Munich, 
Germany) 
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Figure S 2 Influence of MiuA on the formation of small oligomers of actin 
(A, B) MiuA lowers the critical concentration of actin polymerization. The fluorescence intensity as a 
function of time is shown for 50 nM atto488 labeled actin after 1h incubation, without (A) and with (B) 
10x excess of MiuA. (C) FCS curves of 50 nM actin-atto488 with and without MiuA, the emergence 
of a slowly diffusing component due to the formation of small oligomers is observed. (D) The Intensity 
of spikes (in units of the mean count rate) is shown for the respective measurements. Blue squares: 
100 nM actin-atto488, red circles: 100 nM actin-atto488 and 1 μM MiuA. Error bars represent the 
standard error of the mean of three independent measurements. After 30 min of incubation, a higher 
spike intensity is observed for actin in the presence of MiuA. (Results were provided by Prof. Dr. Don 
C. Lamb, Department Chemistry, Ludwig-Maximilians University Munich, Germany) 
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Figure S 3 Binding sites for miuA, phalloidin and jasplakinolide 
Five potential binding sites for MiuA (M1 to M5) obtained by the computer-based docking simulations 
are projected into the G-actin monomer (Protein Data Bank: 3HBT). G-actin: magenta, respective 
binding sites of the compounds: yellow. (Data were provided by Prof. Iris Antes, Protein Modelling 
group, Technical University of Munich, Germany) 
 
M4 
M2 
M5 
M3 M1 
MiuA Phalloidin Jasplakinolide 
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Figure S 4 Structures of the docked Miuraenamide A and after 25 ns of MD equilibration 
A global view of the system is presented in (A) and (B) gives a detailed view of the binding site. Actin 
is shown in cartoon representation, ADP (blue), Ca+ (green) and Miuraenamide A (purple) are shown 
as van der Waals spheres (A) and as sticks (B). Residues interacting with the ligand are shown with 
A B 
C E 
D F 
G H 
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sticks. (C+D) RMSD time-series (Å) of the apo- (C) and holo- (miuraenamide A bound) (D) 
simulations. The black, red, magenta, and blue colors represent the deviations of α carbon atoms of 
the trimer, monomer1, monomer 2 and monomer 3 from the initial structures, respectively. (E+F) The 
deviation of the distances of pairs of monomers (based on the center of mass of the stable β-sheet 
regions of each monomer) from the initial structure as a function of time for the apo- (E) and holo- 
(F) systems. (G) The orientation of Miuraenamide A within the trimer is depicted with an additional 
focus on the interaction between the D-loop of monomer 3 and the ligand of monomer 2 in the inset. 
(H) The difference in packing between the apo- (transparent coloring) and holo- (solid coloring) trimer 
systems is illustrated for a representative structure of the two complexes. (Data were provided by 
Prof. Iris Antes, Protein Modelling group, Technical University of Munich, Germany) 
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Figure S 5 Conformational changes induced by binding of MiuA 
(A) Once MiuA binds to F-actin, the D-loop of monomer 3 moves closer to monomer 2 during the 
molecular dynamics simulation. (B) MiuA and cofilin bound to the F-actin (the position of cofilin is 
shown as bound in the apo-structure with F-actin). The new conformation of the D-loop overlaps with 
the bound conformation of cofilin. (Data were provided by Prof. Iris Antes, Protein Modelling group, 
Technical University of Munich, Germany) 
  
A B 
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Figure S 6  X-ray crystal structure of G-actin in complex with chivosazole A 
(A) Structure of the actin-chivosazole A complex, overall folding topology and domain structure. The 
actin is depicted as ribbon, with the four domains highlighted. The ATP (orange) and chivosazole A 
(green) are shown as stick model, the magnesium ion as sphere (purple). Overlaid, for chivosazole 
A the simulated annealing Fo-DFc difference electron density is contoured at 2.5 (green). (B) 
Superposition of actin structures in complex with macrolides. The actin surface is colored according 
to the surface residue charges and the macrolides are shown as stick models. Chivosazole A (dark 
green, this work), lobophorolide (light green, PDB code 3M6G), jasplakinolide A (cyan; PDB code 
1QZ6) and sphinxolide B (golden; PDB code 2ASO). (C) Mapping of the chivosazole A (green space-
fill model) binding side on the surface of the cryo-EM F-actin structure (PDB code 6BNO). Inset: 
zoom in the F-actin interface (blue) overlaid with the actin-chivosazole A complex (green). The 
DNase-binding loop (residues 40-50) of subdomain 2 interacting with subdomain 1 is shown in red. 
(D) Schematic diagram of the interactions between actin and chivosazole A. Hydrophobic 
interactions are indicated by the red half-circles. The 2D-plot was prepared with LigPlot[90]. (Data 
were provided by Dr. Sabine Schneider, Department of Chemistry, Technical University of Munich, 
Germany)  
A 
C D 
B 
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Figure S 7  
(A) Simulated annealing Fo-DFc difference electron density (contoured at 2.5 σ; green) of Chivo A, 
with the actin surface coloured according to the surface residue charges. (B) Crystal-lattice contacts 
at the ChivoA binding site. (Data were provided by Dr. Sabine Schneider, Department of Chemistry, 
Technical University of Munich, Germany) 
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Figure S 8 Comparison of chivosazole A binding site and the interaction interface of actin 
binding proteins 
(A) cofilin (light pink; PDB code 3J0S), (B) gelsolin (cyan; PDB code 1H1V), (C) MRTF-A (grey, PDB 
code 2V52), (D) thymosin β4 (Tβ4) (golden; PDB code 1T44) and (E) profilin (light green; PDB code 
2BTF). The actin is shown as surface representation colored according to the surface charge. ChivoA 
is depicted as green stick model. The amphiphilic helices of the actin-binding proteins, which pack 
into the target binding grove, are highlighted in pink. (Data were provided by Dr. Sabine Schneider, 
Department of Chemistry, Technical University of Munich, Germany)  
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8.2 Supplementary Tables 
Treatment Total number of 
differentially 
regulated genes 
Number of 
upregulated genes 
Number of 
downregulated genes 
Miuraenamide A (60 nM) 
vs. control 
779 384 395 
Jasplakinolide (120 nM)   
vs. control 
224 132 92 
Miuraenamide A (60 nM) 
vs. Jasplakinolide (120 nM) 
101 55 46 
 
Table S 1 Gene regulation by miuraenamide A and jasplakinolide after 4 h 
Treatment of HUVECs with a well-tolerated concentration of Miuraenamide A (60 nM) or and 
equipotent concentration of jasplakinolide (120 nM) for 4 h caused dramatic effects on transcriptional 
regulation. Assessment of transcriptome was performed by Prof. Dr. Wolfgang Enard (Department 
Biology II, Ludwig-Maximilians University Munich, Germany). 
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GO, ID Term Annotated Significant Expected Fisher 
GO:0071456 cellular response to hypoxia 146 7 1,09 0,00011 
GO:0030509 BMP signaling pathway 90 7 0,67 0,00015 
GO:0030900 forebrain development 213 8 1,6 0,00018 
GO:0045446 endothelial cell differentiation 74 5 0,55 0,00022 
GO:0007568 aging 194 7 1,45 0,0006 
GO:0043280 positive regulation of cysteine-type 
endopeptidase activity involved in 
apoptotic process 
92 5 0,69 0,00061 
GO:0045666 positive regulation of neuron 
differentiation 
202 7 1,51 0,00077 
GO:0043410 positive regulation of MAPK 
cascade 
272 8 2,04 0,00094 
GO:0006935 chemotaxis 295 8 2,21 0,00158 
GO:0032496 response to lipopolysaccharide 177 6 1,33 0,00207 
GO:0002064 epithelial cell development 124 5 0,93 0,00233 
GO:0001558 regulation of cell growth 260 7 1,95 0,00325 
GO:0071902 positive regulation of protein 
serine/threonine kinase activity 
198 6 1,48 0,00361 
GO:0051051 negative regulation of transport 265 7 1,99 0,00361 
GO:0072593 reactive oxygen species metabolic 
process 
149 7 1,12 0,00471 
GO:0051216 cartilage development 110 6 0,82 0,00545 
GO:0043405 regulation of MAP kinase activity 218 6 1,63 0,00576 
GO:0071560 cellular response to transforming 
growth factor beta stimulus 
155 5 1,16 0,00604 
GO:0006979 response to oxidative stress 300 7 2,25 0,00706 
GO:0051155 positive regulation of striated 
muscle cell differentiation 
31 5 0,23 0,00727 
 
Table S 2 Significant gene set enrichment (category "biological process", Fisher's exact test: 
<0.01) based on differentially regulated genes by Miuraenamide A compared to jasplakinolid 
The GOs (gene ontologies) marked in grey are unique for the comparison Miuraenamide A vs. 
jasplakinolide and do not show up in Miuraenamide A or jasplakinolide vs. control (provided by Prof. 
Dr. Wolfgang Enard, Department Biology II, Ludwig-Maximilians University Munich, Germany). 
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ENSEMBL SYMBOL baseMean log2FoldChange pvalue padj 
ENSG00000143869 GDF7 12.1612956 3.211230417 0.00066079 0.04390488 
ENSG00000117707 PROX1 6.9950098 1.200773712 0.00038769 0.02984357 
ENSG00000254409 NA 6.75172368 1.031068621 0.00075856 0.04826523 
ENSG00000146592 CREB5 4.81387076 0.989692802 0.00214647 0.09695071 
ENSG00000134070 IRAK2 13.4395225 0.85821141 0.00065576 0.04361793 
ENSG00000138764 CCNG2 13.0686991 0.847376617 0.00013811 0.01398979 
ENSG00000159167 STC1 22.7951994 0.837013708 1.71E-05 0.00295321 
ENSG00000130522 JUND 41.7888712 0.767387825 3.31E-08 1.97E-05 
ENSG00000196843 ARID5A 23.5057975 0.762749431 6.30E-06 0.00137834 
ENSG00000147324 MFHAS1 15.1412852 0.732925029 0.00140356 0.0727488 
ENSG00000185262 UBALD2 42.8586666 0.64487482 3.38E-07 0.00013123 
ENSG00000131773 KHDRBS3 23.5340208 0.627094638 0.00023705 0.02070649 
ENSG00000176907 C8orf4 26.9181463 0.616227006 6.12E-05 0.00760694 
ENSG00000122861 PLAU 58.8854195 0.594281362 5.34E-07 0.0001904 
ENSG00000102802 MEDAG 20.0934396 0.590968616 0.00142928 0.07353533 
ENSG00000156030 ELMSAN1 64.7755138 0.572897126 8.00E-06 0.00166579 
ENSG00000073756 PTGS2 36.0905195 0.570224831 7.02E-05 0.00836912 
ENSG00000267519 LOC284454 41.4665223 0.560945617 6.59E-05 0.00792582 
ENSG00000130513 GDF15 708.008436 0.517880532 1.74E-13 3.36E-10 
ENSG00000114796 KLHL24 27.0924735 0.509324298 0.00116119 0.06431738 
ENSG00000161940 BCL6B 43.7222369 0.50318591 6.45E-05 0.00786805 
ENSG00000215788 TNFRSF25 32.6352593 0.496333564 0.00065528 0.04360987 
ENSG00000102858 MGRN1 29.1883624 0.471525312 0.0018171 0.08659549 
ENSG00000165434 PGM2L1 36.2370469 0.451787136 0.00092966 0.05523594 
ENSG00000104419 NDRG1 65.4743738 0.433732745 5.07E-05 0.00656209 
ENSG00000008513 ST3GAL1 52.2455518 0.40094068 0.00046526 0.03407745 
ENSG00000173575 CHD2 47.917017 0.399692546 0.00113307 0.06351039 
ENSG00000106144 CASP2 37.0511503 0.383660036 0.00149717 0.07580822 
ENSG00000144580 CNOT9 90.3178913 0.37166965 3.39E-05 0.00489103 
ENSG00000164938 TP53INP1 63.920527 0.370973762 0.00037737 0.0291967 
ENSG00000171056 SOX7 54.8476519 0.360656701 0.00072401 0.04700333 
ENSG00000137834 SMAD6 121.948355 0.3585581 0.0002086 0.01893161 
ENSG00000130340 SNX9 66.2626525 0.355227145 0.00050724 0.03650922 
ENSG00000138434 SSFA2 54.9343108 0.344254459 0.00101624 0.05874504 
ENSG00000107438 PDLIM1 107.23865 0.332260672 0.00053902 0.03816533 
ENSG00000197632 SERPINB2 78.299862 0.326985741 0.00160777 0.07936332 
ENSG00000136802 LRRC8A 235.319363 0.325326803 1.92E-08 1.23E-05 
ENSG00000183578 TNFAIP8L3 90.7877088 0.315874037 0.00036511 0.02855605 
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ENSG00000228470 NA 89.6018438 0.312031431 0.00029326 0.02442774 
ENSG00000158769 F11R 82.0601165 0.302235223 0.00139272 0.07246435 
ENSG00000151012 SLC7A11 82.7056378 0.301238012 0.00127783 0.06819069 
ENSG00000087074 PPP1R15A 106.256495 0.27161909 0.00072546 0.04702655 
ENSG00000213707 NA 140.893306 0.268136758 0.00222089 0.0992403 
ENSG00000011422 PLAUR 148.981947 0.25625363 0.0005689 0.03952355 
ENSG00000157191 NECAP2 119.240373 0.237760585 0.00166523 0.08146062 
ENSG00000162407 PLPP3 172.539066 0.233707345 0.00183159 0.08711557 
ENSG00000134294 SLC38A2 357.910122 0.232223562 0.00010455 0.01136282 
ENSG00000124762 CDKN1A 319.443467 0.228764937 2.38E-05 0.00375222 
ENSG00000229344 NA 5665.93474 0.211642945 9.01E-05 0.0100968 
ENSG00000067082 KLF6 237.579626 0.193719487 0.00115517 0.06422145 
ENSG00000124766 SOX4 1254.7448 0.18198231 0.00222527 0.09932691 
ENSG00000131711 MAP1B 576.803941 0.176298073 3.93E-05 0.00547202 
ENSG00000142192 APP 351.095286 0.162731651 0.00198436 0.0917555 
ENSG00000198786 ND5 838.781205 0.150652582 0.00074444 0.04771955 
ENSG00000125810 CD93 386.776359 0.146201722 0.00204198 0.0933214 
ENSG00000151131 C12orf45 268.382041 -0.21024775 0.00214708 0.09695071 
ENSG00000138385 SSB 185.094093 -0.214006338 0.00142173 0.07334747 
ENSG00000149357 LAMTOR1 139.431261 -0.239179547 0.00079173 0.04957737 
ENSG00000133226 SRRM1 375.102906 -0.272147429 0.00051291 0.0367654 
ENSG00000115875 SRSF7 119.235007 -0.297525344 0.00020567 0.01881552 
ENSG00000139168 ZCRB1 131.131784 -0.304510218 0.0014063 0.07282885 
ENSG00000133773 CCDC59 85.2291742 -0.307601768 0.00201229 0.09246211 
ENSG00000238072 NA 69.5976404 -0.307819146 0.00215496 0.09707743 
ENSG00000048162 NOP16 134.341148 -0.313659024 2.15E-05 0.00348392 
ENSG00000240298 NA 62.3763571 -0.319876639 0.00191628 0.08974243 
ENSG00000179131 NA 77.2328996 -0.331069114 0.00216514 0.09750007 
ENSG00000164741 DLC1 51.9483834 -0.345891822 0.00185087 0.08762236 
ENSG00000142871 CYR61 235.361041 -0.370878102 0.00016354 0.01591759 
ENSG00000266086 NA 71.1093436 -0.392386662 5.06E-05 0.00655592 
ENSG00000155850 SLC26A2 45.6745027 -0.444084894 0.000238 0.02074545 
ENSG00000179144 GIMAP7 73.1894221 -0.469074649 4.46E-05 0.00597939 
ENSG00000080608 PUM3 104.021307 -0.474190625 1.08E-05 0.0020823 
ENSG00000099260 PALMD 77.5489432 -0.483968208 9.46E-06 0.00187135 
ENSG00000237049 NA 30.5010276 -0.493060911 0.00108841 0.06171657 
ENSG00000137463 MGARP 24.9273743 -0.521143856 0.00154892 0.077368 
ENSG00000196873 CBWD3 26.5944043 -0.552697818 0.00045917 0.03376768 
ENSG00000117152 RGS4 33.6028624 -0.589116209 0.00013311 0.01361863 
8 Appendix 
 
 
86 
ENSG00000120738 EGR1 15.7402692 -0.629288447 0.0019559 0.09096887 
ENSG00000099860 GADD45B 22.2964557 -0.635534712 0.00030033 0.02486209 
ENSG00000107984 DKK1 99.9401769 -0.650902736 6.50E-05 0.0078897 
ENSG00000078401 EDN1 260.830597 -0.680275946 7.62E-09 5.73E-06 
ENSG00000244756 NA 23.7608697 -0.767663412 1.30E-05 0.00241149 
ENSG00000157168 NRG1 20.6776412 -0.778532334 2.79E-05 0.00420651 
ENSG00000180104 EXOC3 15.8029714 -0.797772381 0.00011715 0.01231661 
ENSG00000125378 BMP4 24.0942604 -0.826740033 6.51E-05 0.0078897 
ENSG00000124523 SIRT5 8.94292235 -0.852466902 0.0010919 0.06182819 
ENSG00000118523 CTGF 679.769853 -0.85885136 1.07E-14 2.38E-11 
ENSG00000148677 ANKRD1 3885.6597 -0.889321614 9.17E-13 1.55E-09 
ENSG00000178882 RFLNA 23.2346925 -1.022347951 3.40E-07 0.00013141 
ENSG00000243537 NA 4.24821161 -1.286558947 0.00148006 0.07533573 
ENSG00000128383 APOBEC3A 3.57717737 -1.405510384 0.00144089 0.07392863 
ENSG00000171016 PYGO1 3.26208156 -1.439309644 0.00132005 0.06963448 
ENSG00000218472 NA 5.56373608 -1.588729529 0.00032532 0.02634036 
ENSG00000275757 LOC100008587 10.1139674 -1.765498882 2.05E-05 0.00338016 
ENSG00000235332 NA 2.51970313 -1.860462883 0.00089551 0.05386374 
ENSG00000109846 CRYAB 5.56763057 -2.016951635 5.58E-06 0.0012453 
ENSG00000166165 CKB 9.31435082 -2.276836856 3.17E-05 0.00467047 
ENSG00000250397 NA 1.89401328 -2.543100155 0.00187365 0.08825596 
ENSG00000231034 NA 2.01281478 -2.603037911 0.00179789 0.08591501 
ENSG00000234576 NA 7.74783861 -3.140189044 0.00080679 0.05013368 
ENSG00000278806 NA 10.140733 -4.458140103 1.89E-05 0.00316203 
 
Table S 3 List of the genes that are differently regulated in HUVEC cells treated with Miu A vs. 
Jaspla 
(provided by Prof. Dr. Wolfgang Enard, Department Biology II, Ludwig-Maximilians University Munich, 
Germany). 
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GO,ID Term Annotated Significant Expected Fisher ratio 
GO:0071260 cellular response to mechanical stimulus 56 11 2.87 0.00011 19.6 
GO:0045987 positive regulation of smooth muscle contraction 11 5 0.56 0.00012 45.5 
GO:0042273 ribosomal large subunit biogenesis 57 11 2.92 0.00012 19.3 
GO:0045214 sarcomere organization 18 6 0.92 0.00019 33.3 
GO:0030335 positive regulation of cell migration 265 31 13.59 0.0002 11.7 
GO:0038096 Fc-gamma receptor signaling pathway involved in phagocytosis 62 11 3.18 0.00027 17.7 
GO:0010592 positive regulation of lamellipodium assembly 13 5 0.67 0.00032 38.5 
GO:0007015 actin filament organization 253 39 12.97 0.00036 15.4 
GO:0045601 regulation of endothelial cell differentiation 20 6 1.03 0.00037 30 
GO:0090151 establishment of protein localization to mitochondrial membrane 14 5 0.72 0.00047 35.7 
GO:2001222 regulation of neuron migration 21 6 1.08 0.00049 28.6 
GO:0030220 platelet formation 15 5 0.77 0.00068 33.3 
GO:0030901 midbrain development 59 10 3.03 0.00075 16.9 
GO:0002064 epithelial cell development 124 19 6.36 0.00081 15.3 
GO:0032970 regulation of actin filament-based process 231 34 11.84 0.00092 14.7 
GO:0007254 JNK cascade 130 16 6.67 0.00097 12.3 
GO:0060996 dendritic spine development 61 10 3.13 0.00098 16.4 
GO:0070423 nucleotide-binding oligomerization domain containing signaling pathway 32 7 1.64 0.00098 21.9 
GO:0071347 cellular response to interleukin-1 51 9 2.61 0.00101 17.6 
GO:0008361 regulation of cell size 107 14 5.49 0.00109 13.1 
GO:0048146 positive regulation of fibroblast proliferation 33 7 1.69 0.00119 21.2 
GO:0001503 ossification 240 24 12.31 0.00131 10 
GO:0060333 interferon-gamma-mediated signaling pathway 53 9 2.72 0.00134 17 
GO:0071417 cellular response to organonitrogen compound 341 31 17.48 0.00136 9.1 
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GO:0006954 inflammatory response 312 29 16 0.00137 9.3 
GO:0034332 adherens junction organization 98 13 5.02 0.00143 13.3 
GO:0007163 establishment or maintenance of cell polarity 123 15 6.31 0.00152 12.2 
GO:0002181 cytoplasmic translation 44 8 2.26 0.00156 18.2 
GO:0006937 regulation of muscle contraction 66 14 3.38 0.00166 21.2 
GO:1900026 positive regulation of substrate adhesion-dependent cell spreading 26 6 1.33 0.00169 23.1 
GO:0016601 Rac protein signal transduction 26 6 1.33 0.00169 23.1 
GO:0007588 excretion 18 5 0.92 0.00171 27.8 
GO:1902905 positive regulation of supramolecular fiber organization 120 18 6.15 0.00174 15 
GO:0022618 ribonucleoprotein complex assembly 177 19 9.08 0.0018 10.7 
GO:2000146 negative regulation of cell motility 154 18 7.9 0.00229 11.7 
GO:0017148 negative regulation of translation 129 15 6.61 0.00245 11.6 
GO:0002262 myeloid cell homeostasis 104 13 5.33 0.00246 12.5 
GO:0051092 positive regulation of NF-kappaB transcription factor activity 93 12 4.77 0.00273 12.9 
GO:0030260 entry into host cell 93 12 4.77 0.00273 12.9 
GO:0035094 response to nicotine 20 5 1.03 0.00284 25 
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling 133 15 6.82 0.0033 11.3 
GO:0071356 cellular response to tumor necrosis factor 187 19 9.59 0.00337 10.2 
GO:0043542 endothelial cell migration 122 14 6.26 0.0038 11.5 
GO:0051216 cartilage development 110 13 5.64 0.00404 11.8 
GO:0030216 keratinocyte differentiation 62 9 3.18 0.00409 14.5 
GO:0007179 transforming growth factor beta receptor signaling pathway 123 14 6.31 0.00409 11.4 
GO:0000187 activation of MAPK activity 86 11 4.41 0.00432 12.8 
GO:0034314 Arp2/3 complex-mediated actin nucleation 31 6 1.59 0.00434 19.4 
GO:0061028 establishment of endothelial barrier 31 6 1.59 0.00434 19.4 
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GO:0048333 mesodermal cell differentiation 22 5 1.13 0.00442 22.7 
GO:0010470 regulation of gastrulation 22 5 1.13 0.00442 22.7 
GO:0003206 cardiac chamber morphogenesis 75 10 3.85 0.00474 13.3 
GO:0045446 endothelial cell differentiation 74 15 3.79 0.00479 20.3 
GO:0030048 actin filament-based movement 67 12 3.44 0.00503 17.9 
GO:0002009 morphogenesis of an epithelium 341 29 17.48 0.00505 8.5 
GO:1901185 negative regulation of ERBB signaling pathway 42 7 2.15 0.00505 16.7 
GO:0008064 regulation of actin polymerization or depolymerization 123 20 6.31 0.00516 16.3 
GO:0097421 liver regeneration 23 5 1.18 0.00542 21.7 
GO:0030198 extracellular matrix organization 182 18 9.33 0.00565 9.9 
GO:0001525 angiogenesis 269 28 13.79 0.00613 10.4 
GO:0061842 microtubule organizing center localization 24 5 1.23 0.00656 20.8 
GO:0030195 negative regulation of blood coagulation 24 5 1.23 0.00656 20.8 
 
Table S 4 List of the gene ontologies (GO) that are significantly regulated by MiuA treatment 
(provided by Prof. Dr. Wolfgang Enard, Department Biology II, Ludwig-Maximilians University Munich, Germany). 
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GO,ID Term Annotated Significant Expected Fisher ratio 
GO:0030335 positive regulation of cell migration 265 14 4.39 0.00013 5.3 
GO:0007015 actin filament organization 253 22 4.19 0.00014 8.7 
GO:0034314 Arp2/3 complex-mediated actin nucleation 31 5 0.51 0.00014 16.1 
GO:0007163 establishment or maintenance of cell polarity 123 9 2.04 0.0002 7.3 
GO:0002576 platelet degranulation 80 7 1.33 0.00035 8.8 
GO:0007229 integrin-mediated signaling pathway 61 6 1.01 0.00049 9.8 
GO:0071346 cellular response to interferon-gamma 71 6 1.18 0.00111 8.5 
GO:0003206 cardiac chamber morphogenesis 75 8 1.24 0.00116 10.7 
GO:0006937 regulation of muscle contraction 66 8 1.09 0.00194 12.1 
GO:0032956 regulation of actin cytoskeleton organization 210 17 3.48 0.00198 8.1 
GO:0003014 renal system process 55 5 0.91 0.00209 9.1 
GO:2000379 positive regulation of reactive oxygen species metabolic process 55 5 0.91 0.00209 9.1 
GO:0045165 cell fate commitment 110 7 1.82 0.0023 6.4 
GO:0048145 regulation of fibroblast proliferation 57 5 0.94 0.00246 8.8 
GO:0019221 cytokine-mediated signaling pathway 320 13 5.3 0.00253 4.1 
GO:0000910 cytokinesis 113 7 1.87 0.00268 6.2 
GO:0030509 BMP signaling pathway 90 6 1.49 0.00374 6.7 
GO:0032970 regulation of actin filament-based process 231 20 3.83 0.00375 8.7 
GO:0051092 positive regulation of NF-kappaB transcription factor activity 93 6 1.54 0.00439 6.5 
GO:0009612 response to mechanical stimulus 124 7 2.05 0.00449 5.6 
GO:0002064 epithelial cell development 124 7 2.05 0.00449 5.6 
GO:0048812 neuron projection morphogenesis 344 13 5.7 0.00468 3.8 
GO:0032535 regulation of cellular component size 236 17 3.91 0.00547 7.2 
GO:0051017 actin filament bundle assembly 98 6 1.62 0.00567 6.1 
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GO:0045860 positive regulation of protein kinase activity 312 12 5.17 0.00568 3.8 
GO:0043588 skin development 130 7 2.15 0.00581 5.4 
GO:0034333 adherens junction assembly 71 5 1.18 0.00634 7 
GO:0002009 morphogenesis of an epithelium 341 17 5.65 0.00637 5 
GO:0006936 muscle contraction 153 15 2.53 0.00639 9.8 
GO:0030307 positive regulation of cell growth 103 6 1.71 0.0072 5.8 
GO:0001525 angiogenesis 269 13 4.46 0.00737 4.8 
GO:0071560 cellular response to transforming growth factor beta stimulus 155 10 2.57 0.00753 6.5 
GO:0045446 endothelial cell differentiation 74 5 1.23 0.00755 6.8 
GO:0071158 positive regulation of cell cycle arrest 74 5 1.23 0.00755 6.8 
GO:0007160 cell-matrix adhesion 139 7 2.3 0.00829 5 
GO:0008360 regulation of cell shape 108 6 1.79 0.00901 5.6 
GO:0001933 negative regulation of protein phosphorylation 292 11 4.84 0.00925 3.8 
GO:0003231 cardiac ventricle development 78 7 1.29 0.00926 9 
GO:0008217 regulation of blood pressure 78 5 1.29 0.00938 6.4 
 
Table S 5 List of the gene ontologies (GO) that are significantly regulated by Jaspla treatment 
(provided by Prof. Dr. Wolfgang Enard, Department Biology II, Ludwig-Maximilians University Munich, Germany). 
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ENSEMBL symbol log2 fold change adjusted p value 
ENSG00000278806 NA -4,711252094 0,00139022 
ENSG00000234576 NA -4,564728721 0,00011785 
ENSG00000225718 NA -3,510179757 0,00229876 
ENSG00000231034 NA -3,41544532 0,00626786 
ENSG00000229735 NA -3,127949743 0,01961863 
ENSG00000166165 CKB -2,704005339 9,92E-05 
ENSG00000236571 NA -2,654571366 0,04171752 
ENSG00000233829 NA -2,651032822 0,05329787 
ENSG00000268391 NA -2,381502657 0,03993551 
ENSG00000251340 MTCYBP35 -2,175472007 0,04915397 
ENSG00000266920 NA -1,851983819 0,03641245 
ENSG00000156466 GDF6 -1,765741656 8,92E-08 
ENSG00000255266 NA -1,676356622 0,05183135 
ENSG00000109846 CRYAB -1,669887718 0,00381191 
ENSG00000078401 EDN1 -1,589883974 3,40E-39 
ENSG00000165702 GFI1B -1,569041341 0,03693842 
ENSG00000118523 CTGF -1,485906037 1,37E-38 
ENSG00000125378 BMP4 -1,476586972 2,56E-13 
ENSG00000107984 DKK1 -1,451643699 8,46E-19 
ENSG00000235387 SPAAR -1,345679574 1,47E-07 
ENSG00000144647 POMGNT2 -1,296480359 0,00338969 
ENSG00000146674 IGFBP3 -1,271827367 0,04492982 
ENSG00000148677 ANKRD1 -1,264103878 7,10E-22 
ENSG00000243256 NA -1,176852375 0,00091206 
ENSG00000081692 JMJD4 -1,134625587 0,00650101 
ENSG00000176697 BDNF -1,12664306 0,00611232 
ENSG00000163739 CXCL1 -1,106669894 6,90E-08 
ENSG00000159399 HK2 -1,100730212 0,01758736 
ENSG00000142871 CYR61 -1,084531632 2,88E-23 
ENSG00000120217 CD274 -1,042662377 0,05106095 
ENSG00000226915 NA -1,018300709 0,04277393 
ENSG00000112029 FBXO5 -0,977233153 0,0032306 
ENSG00000235045 NA -0,954167559 0,01668169 
ENSG00000117152 RGS4 -0,932751547 4,15E-08 
ENSG00000151093 OXSM -0,930204096 0,02212105 
ENSG00000226860 NA -0,921720286 0,01930647 
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ENSG00000104833 TUBB4A -0,920009066 0,02173595 
ENSG00000164815 ORC5 -0,898115897 0,01709753 
ENSG00000178882 RFLNA -0,891361029 0,00022723 
ENSG00000157168 NRG1 -0,767036575 0,00232789 
ENSG00000132436 FIGNL1 -0,736941866 0,01385136 
ENSG00000115875 SRSF7 -0,716940606 1,32E-15 
ENSG00000183741 CBX6 -0,713469689 0,00359312 
ENSG00000092098 RNF31 -0,708179646 0,04327808 
ENSG00000127824 TUBA4A -0,704994591 0,02647267 
ENSG00000179431 FJX1 -0,68995993 0,01579507 
ENSG00000182253 SYNM -0,688613397 0,01951484 
ENSG00000146834 MEPCE -0,686588486 0,02601277 
ENSG00000214870 NA -0,682478229 0,00570223 
ENSG00000099860 GADD45B -0,678618177 0,01501352 
ENSG00000144120 TMEM177 -0,67293138 0,00121859 
ENSG00000122971 ACADS -0,665025042 0,01780188 
ENSG00000214289 NA -0,65332803 0,00238371 
ENSG00000189369 GSPT2 -0,646458553 0,01410789 
ENSG00000155438 NIFK -0,635431774 4,79E-05 
ENSG00000137267 TUBB2A -0,605154126 3,09E-07 
ENSG00000244756 NA -0,604714512 0,01422129 
ENSG00000099260 PALMD -0,585014555 1,28E-05 
ENSG00000119408 NEK6 -0,572140637 0,00839702 
ENSG00000188229 TUBB4B -0,558492083 2,43E-10 
ENSG00000228495 NA -0,555991338 0,00017305 
ENSG00000137285 TUBB2B -0,555309058 1,21E-07 
ENSG00000130340 SNX9 0,747090146 5,69E-11 
ENSG00000275023 MLLT6 0,747468252 0,01765458 
ENSG00000166510 CCDC68 0,748366521 0,00787823 
ENSG00000130513 GDF15 0,749992949 3,82E-25 
ENSG00000173575 CHD2 0,752044832 2,49E-08 
ENSG00000088826 SMOX 0,761299352 0,00209826 
ENSG00000257242 LINC01619 0,761719758 1,23E-13 
ENSG00000144560 VGLL4 0,769596185 0,00090707 
ENSG00000023287 RB1CC1 0,778228714 3,01E-05 
ENSG00000215788 TNFRSF25 0,794904425 6,90E-06 
ENSG00000188559 RALGAPA2 0,796218801 0,02130162 
ENSG00000174718 KIAA1551 0,802010826 0,00870919 
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ENSG00000157514 TSC22D3 0,806541361 0,02471592 
ENSG00000167106 FAM102A 0,811860557 0,01293999 
ENSG00000168916 ZNF608 0,82181994 0,03610715 
ENSG00000101445 PPP1R16B 0,826356979 0,00650101 
ENSG00000159167 STC1 0,833760609 0,0019435 
ENSG00000100784 RPS6KA5 0,885357525 0,00575559 
ENSG00000245532 NEAT1 0,891768378 1,02E-21 
ENSG00000140199 SLC12A6 0,893582467 0,02629094 
ENSG00000162852 CNST 0,896329093 0,01267482 
ENSG00000152518 ZFP36L2 0,91337122 2,86E-13 
ENSG00000119138 KLF9 0,916987276 0,00128791 
ENSG00000109787 KLF3 0,951547018 8,52E-05 
ENSG00000161940 BCL6B 0,970565409 4,99E-14 
ENSG00000127528 KLF2 0,97722175 3,91E-13 
ENSG00000073756 PTGS2 1,01561324 2,43E-10 
ENSG00000100916 BRMS1L 1,039595297 0,03534367 
ENSG00000136630 HLX 1,067377216 2,26E-08 
ENSG00000164463 CREBRF 1,149750682 0,00069663 
ENSG00000158859 ADAMTS4 1,178642387 4,23E-23 
ENSG00000183337 BCOR 1,183057282 0,00381859 
ENSG00000138061 CYP1B1 1,271957146 2,58E-06 
ENSG00000154734 ADAMTS1 1,277419617 8,97E-20 
ENSG00000246451 NA 1,306544402 0,02269402 
ENSG00000136826 KLF4 1,407640121 0,00367329 
ENSG00000154240 CEP112 1,572562073 0,01110282 
ENSG00000266010 GATA6-AS1 2,120515199 0,03267041 
ENSG00000134323 MYCN 2,493810056 0,03274506 
 
Table S 6 List of genes significantly regulated in HUVECs by treatment with ChivoA 
62 genes were downregulated and 39 genes were upregulated after treatment with chivosazole A 
(20 nM ChivoA for 4h). Orange: down regulated genes, green: upregulated genes. (provided by Prof. 
Dr. Wolfgang Enard, Department Biology II, Ludwig-Maximilians University Munich, Germany). 
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ENSEMBL symbol log2 fold change adjusted p value 
ENSG00000234576 NA -5,44594474 2,64E-05 
ENSG00000278806 NA -4,5534863 0,01021061 
ENSG00000225718 NA -3,65942707 0,0083952 
ENSG00000166165 CKB -3,64435677 4,33E-05 
ENSG00000231034 NA -3,45474852 0,02475462 
ENSG00000229735 NA -3,29860145 0,0383754 
ENSG00000125378 BMP4 -1,84640849 4,19E-13 
ENSG00000171388 APLN -1,75669329 1,38E-08 
ENSG00000156466 GDF6 -1,65336517 5,28E-05 
ENSG00000118523 CTGF -1,5886176 5,97E-37 
ENSG00000148677 ANKRD1 -1,50746647 2,70E-27 
ENSG00000078401 EDN1 -1,49884512 2,73E-28 
ENSG00000142871 CYR61 -1,48015156 1,25E-31 
ENSG00000176697 BDNF -1,30977432 0,01587802 
ENSG00000107984 DKK1 -1,21745678 2,50E-10 
ENSG00000157168 NRG1 -1,09048674 0,00032156 
ENSG00000099860 GADD45B -1,08030402 0,00090707 
ENSG00000176641 RNF152 -1,03290295 5,77E-06 
ENSG00000162614 NEXN -1,0081072 5,65E-05 
ENSG00000117152 RGS4 -0,93498945 1,91E-05 
ENSG00000214289 NA -0,9112063 0,00032483 
ENSG00000235926 NA -0,83259571 0,0310095 
ENSG00000074590 NUAK1 -0,82519552 0,02770423 
ENSG00000235387 SPAAR -0,81742293 0,03057397 
ENSG00000275342 PRAG1 -0,81729627 0,00468475 
ENSG00000178882 RFLNA -0,80660113 0,01668169 
ENSG00000144120 TMEM177 -0,74529577 0,00346445 
ENSG00000065613 SLK 0,55832331 0,00321601 
ENSG00000173210 ABLIM3 0,56917767 0,04387971 
ENSG00000119899 SLC17A5 0,57109907 0,04076403 
ENSG00000173575 CHD2 0,57492698 0,00229876 
ENSG00000198873 GRK5 0,58148422 0,01506679 
ENSG00000106537 TSPAN13 0,5816018 0,02516905 
ENSG00000123094 RASSF8 0,5971009 0,03210881 
ENSG00000138434 SSFA2 0,59797009 0,00017947 
ENSG00000023287 RB1CC1 0,60298942 0,02400581 
ENSG00000120875 DUSP4 0,60568084 3,11E-06 
ENSG00000115993 TRAK2 0,61059133 0,03266839 
ENSG00000173218 VANGL1 0,61273784 0,03479464 
ENSG00000114796 KLHL24 0,61950604 0,02182263 
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ENSG00000169554 ZEB2 0,61984925 0,00360596 
ENSG00000083223 ZCCHC6 0,62899774 0,02330445 
ENSG00000073756 PTGS2 0,62948363 0,0153939 
ENSG00000270106 TSNAX-DISC1 0,62954492 0,02547031 
ENSG00000081189 MEF2C 0,63448471 3,93E-05 
ENSG00000130766 SESN2 0,63581621 0,02701907 
ENSG00000153885 KCTD15 0,64004924 0,04305272 
ENSG00000102802 MEDAG 0,64634328 0,03720889 
ENSG00000198844 ARHGEF15 0,646879 0,00113829 
ENSG00000182208 MOB2 0,64897713 0,02193628 
ENSG00000128284 APOL3 0,66574637 0,00966076 
ENSG00000057704 TMCC3 0,66910573 0,0240483 
ENSG00000136237 RAPGEF5 0,67799611 0,04259377 
ENSG00000147421 HMBOX1 0,68095517 0,00398138 
ENSG00000245532 NEAT1 0,68596589 2,29E-10 
ENSG00000173706 HEG1 0,68962416 7,28E-05 
ENSG00000185262 UBALD2 0,6984385 4,00E-05 
ENSG00000270087 NA 0,69973386 0,03080426 
ENSG00000176438 SYNE3 0,70446053 0,03633968 
ENSG00000182704 TSKU 0,71198787 0,00389128 
ENSG00000106829 TLE4 0,71776541 0,00855571 
ENSG00000139117 CPNE8 0,71785387 0,0302548 
ENSG00000008294 SPAG9 0,72305503 7,15E-07 
ENSG00000139112 GABARAPL1 0,73052906 1,35E-05 
ENSG00000162522 KIAA1522 0,73605251 0,04171752 
ENSG00000127528 KLF2 0,73714378 3,44E-05 
ENSG00000148120 C9orf3 0,74059138 0,0180949 
ENSG00000031081 ARHGAP31 0,75725126 0,0002442 
ENSG00000174718 KIAA1551 0,76454041 0,04466995 
ENSG00000134954 ETS1 0,78045459 0,00354444 
ENSG00000235750 KIAA0040 0,79040678 0,0053003 
ENSG00000152518 ZFP36L2 0,79056843 3,09E-07 
ENSG00000111276 CDKN1B 0,79946036 0,0124363 
ENSG00000139679 LPAR6 0,82781059 0,00228863 
ENSG00000161940 BCL6B 0,83129616 1,71E-07 
ENSG00000166510 CCDC68 0,88179459 0,00270354 
ENSG00000100784 RPS6KA5 0,92198304 0,01353423 
ENSG00000108840 HDAC5 0,93221944 0,01147244 
ENSG00000144560 VGLL4 0,93995395 9,12E-05 
ENSG00000154734 ADAMTS1 0,95255394 1,10E-07 
ENSG00000157514 TSC22D3 0,9609219 0,00971846 
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ENSG00000106546 AHR 0,9998206 3,92E-07 
ENSG00000143127 ITGA10 1,00085755 0,00029991 
ENSG00000136630 HLX 1,09595384 3,49E-07 
ENSG00000090776 EFNB1 1,1885352 1,09E-10 
ENSG00000159167 STC1 1,36864162 1,77E-09 
ENSG00000158859 ADAMTS4 1,4528086 3,95E-31 
ENSG00000138061 CYP1B1 1,75541074 7,36E-12 
ENSG00000143869 GDF7 3,15558201 0,03633968 
 
Table S 7 List of genes significantly regulated in HUVECs by treatment with LatB 
27 genes were downregulated and 62 upregulated with latrunculin B (250 nM LatB for 4h). Orange: 
down regulated genes, green: upregulated genes. (provided by Prof. Dr. Wolfgang Enard, 
Department Biology II, Ludwig-Maximilians University Munich, Germany). 
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ENSEMBL ChivoA ENSEMBL LatB 
ENSG00000251340 MTCYBP35 ENSG00000171388 APLN 
ENSG00000109846 CRYAB ENSG00000176641 RNF152 
ENSG00000165702 GFI1B ENSG00000162614 NEXN 
ENSG00000144647 POMGNT2 ENSG00000074590 NUAK1 
ENSG00000146674 IGFBP3 ENSG00000275342 PRAG1 
ENSG00000081692 JMJD4 ENSG00000065613 SLK 
ENSG00000163739 CXCL1 ENSG00000173210 ABLIM3 
ENSG00000159399 HK2 ENSG00000119899 SLC17A5 
ENSG00000120217 CD274 ENSG00000198873 GRK5 
ENSG00000112029 FBXO5 ENSG00000106537 TSPAN13 
ENSG00000151093 OXSM ENSG00000123094 RASSF8 
ENSG00000104833 TUBB4A ENSG00000138434 SSFA2 
ENSG00000164815 ORC5 ENSG00000120875 DUSP4 
ENSG00000132436 FIGNL1 ENSG00000115993 TRAK2 
ENSG00000115875 SRSF7 ENSG00000173218 VANGL1 
ENSG00000183741 CBX6 ENSG00000114796 KLHL24 
ENSG00000092098 RNF31 ENSG00000169554 ZEB2 
ENSG00000127824 TUBA4A ENSG00000083223 ZCCHC6 
ENSG00000179431 FJX1 ENSG00000270106 TSNAX-DISC1 
ENSG00000182253 SYNM ENSG00000081189 MEF2C 
ENSG00000146834 MEPCE ENSG00000130766 SESN2 
ENSG00000122971 ACADS ENSG00000153885 KCTD15 
ENSG00000189369 GSPT2 ENSG00000102802 MEDAG 
ENSG00000155438 NIFK ENSG00000198844 ARHGEF15 
ENSG00000137267 TUBB2A ENSG00000182208 MOB2 
ENSG00000099260 PALMD ENSG00000128284 APOL3 
ENSG00000119408 NEK6 ENSG00000057704 TMCC3 
ENSG00000188229 TUBB4B ENSG00000136237 RAPGEF5 
ENSG00000137285 TUBB2B ENSG00000147421 HMBOX1 
ENSG00000130340 SNX9 ENSG00000173706 HEG1 
ENSG00000275023 MLLT6 ENSG00000185262 UBALD2 
ENSG00000130513 GDF15 ENSG00000176438 SYNE3 
ENSG00000088826 SMOX ENSG00000182704 TSKU 
ENSG00000257242 LINC01619 ENSG00000106829 TLE4 
ENSG00000215788 TNFRSF25 ENSG00000139117 CPNE8 
ENSG00000188559 RALGAPA2 ENSG00000008294 SPAG9 
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ENSG00000167106 FAM102A ENSG00000139112 GABARAPL1 
ENSG00000168916 ZNF608 ENSG00000235750 KIAA0040 
ENSG00000101445 PPP1R16B ENSG00000111276 CDKN1B 
ENSG00000119138 KLF9 ENSG00000139679 LPAR6 
ENSG00000109787 KLF3 ENSG00000108840 HDAC5 
ENSG00000100916 BRMS1L ENSG00000106546 AHR 
ENSG00000164463 CREBRF ENSG00000143127 ITGA10 
ENSG00000183337 BCOR ENSG00000090776 EFNB1 
ENSG00000136826 KLF4 ENSG00000143869 GDF7 
ENSG00000154240 CEP112 
ENSG00000266010 GATA6-AS1 
ENSG00000134323 MYCN 
 
Table S 8 List of genes significantly regulated in HUVECs only by ChivoA or only by LatB 
29 genes were only downregulated by chivosazole A, but not by latrunculin B, and 19 were only 
upregulated by chivosazole A and not by latrunculin B. 5 genes were specifically downregulated and 
40 upregulated by latrunculin B in contrast to chivosazole A. Orange: down regulated genes, green: 
upregulated genes (provided by Prof. Dr. Wolfgang Enard, Department Biology II, Ludwig-
Maximilians University Munich, Germany). 
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8.4 Abbreviations  
Table 1 List of Abbreviations 
2D two-dimensional 
3D three-dimensional 
Å Ångstrom, 10−10 meter 
ABPs Actin binding proteins 
ADF actin-depolymerizing factor 
ANOVA Analysis of variance between groups 
APS Ammoniumpersulfate 
ADP Adenosine diphosphate 
ATP Adenosine triphosphate 
BSA Bovine serum albumin 
Cc Critical concentration 
CFL1 Cofilin-1 
ChivoA Chivosazole A 
ChivoF Chivosazole F 
cm, cm2 Centimetre, Square centimetre 
COM Center-of-masses 
DE Differential expression 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl sulfoxide 
DNA Deoxyribonucleic acid 
DTT Dithiothreithol 
ECGM Endothelial cell growth medium 
EDC 1-ethyl-3-(3-dimethylaminopropyl)- carbodiimide 
EDTA Ethylenediaminetetraacetic acid 
EGTA Ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid  
EM Electron microscopy 
EMT Epithelial-to-mesenchymal transition 
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FCS (1) Fetal calf serum 
FCS (2) Fluorescence correlation spectroscopy 
Fig. Figure 
FMI Forward migration index 
g Gram 
GOs Gene ontologies 
h Hour 
HUVECs Human umbilical vein endothelial cells 
IC 50 Half maximal inhibitory concentration 
i.e. Id est (that is) 
Jaspla Jasplakinolide 
kcal/mol Kilocalorie per mole 
kDa Kilodalton 
L Liter 
LatB Latrunculin B 
M Molar 
MD Molecular dynamics 
MES 2-(N-morpholino)-ethanesulfonic acid 
MET Mesenchymal-to-epithelial transition 
mg, ml, mM, mm Milligram, milliliter, millimolar, millimetre 
min Minute 
MiuA Miuraenamide A 
MRTF Myocardin related transcription factor 
nM, nm Nanomolar, Nanometre 
PBS Phosphate Buffered Saline 
Pen / Strep Penicillin/Streptomycin 
PFA Paraformaldehyde 
pH Potential of hydrogen 
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RMSD Root mean square deviations 
rpm Revolutions per minute 
RT Room temperature 
s Second 
SATB1 special AT-rich sequence-binding protein 1 
SEM Standard error of the mean value 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
Tβ4 Thymosin β4 
TCE 2,2,2-Trichloroethanol 
T/E Trypsin/EDTA 
TEMED N, N, N’, N’ tetramethylethylene diamine 
TIRF Total internal reflection fluorescence 
Tris Trishydroxymethylaminomethane 
V Volt 
v/v  Volume per volume 
w/v Weight per volume 
μg, μl, μM, μm Microgram, microliter, micromolar, micrometre 
°C Degree Celsius 
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